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 Pneumonia is a respiratory disease that affects millions of people around the world, 
the majority of which live in developing countries. While a significant proportion of 
childhood pneumonia has been reduced with modern medicine, pneumonia remains the 
leading cause of death for children under five. In Gambia, the introduction of a 13-valent 
pneumococcal conjugate vaccine sparked fears of replacement carriage of Streptococcus 
pneumoniae in children, and a surveillance system was set up to monitor the effectiveness 
of the vaccine, as well as its effects on the population. 
Methods 
 The surveillance system collected data on Invasive Pneumococcal Disease (IPD) and 
Radiologically Confirmed Pneumonia (RCP) in the Upper River Region of the Gambia for a 
period of several years (2007-ongoing), in addition to demographic and geographic data. 
Cases of IPD and RCP were mapped in a GIS and then analysed using statistical scanning 
software to identify any patterns through space or time to determine any spatio-temporal 
differences. Additionally, a new adaptive kernel smoothing method was used to produce 
risk surfaces, allowing diseases to be directly compared.  
Results 
 IPD and RCP showed differing mapping characteristics across some basic 
demographic information (age grouping, vaccination status, and ethnicity). Vaccine type 
serotypes differed from non-vaccine types, with PCV-13 coverage appearing to protect 
against its target serotypes. Overall significant clustering of IPD “spread” outwards from the 
original baseline cluster to surrounding regions, while RCP clusters move eastwards after 
the baseline period, and cover a much wider area, indicating greatly increased rates. Slight 
variations occur between age groupings, representing the higher burden of IPD at a younger 
age, while RCP affects slightly older children. Hotspots of vaccine type serotypes were 
identified, as well as non-vaccine type, indicating areas of interest for improved vaccination 
coverage. Significant differences in geospatial distribution of cases occur for both IPD and 
RCP during Before and After time periods of the vaccination program, as evidenced by the 
shift in clustering across the map. Incidence rates show peaks in IPD in 2010 (82/100,000), 
but show an overall decrease over time, while RCP shows the highest peak in 2012 
(521/100,000), with an increasing trend over time.  
Conclusion 
The impact of pneumococcal conjugate vaccines is having a noticeable effect on IPD 
and RCP cases across time and age groups. The differing characteristics of the diseases 
showed initial geographic similarities at baseline, which have diverged as the time period 
goes on. Clusters are expanding and shifting locations for both diseases, while hotspots of 
disease continue to pop up throughout different time periods. The overall reduction in IPD 
cases indicates intermediate success for the PCV-13 program, while the hotspots of both 
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Chapter 1 – Introduction 
 
This thesis describes the distribution of childhood pneumonia and pneumococcal 
disease in rural Gambia. It considers the spatiotemporal differences between radiological 
pneumonia and invasive pneumococcal disease, and the implications this has for 
management and control in a developing country.  
The primary objective of the project was to map the confirmed cases of radiologic 
pneumonia as well as confirmed cases of IPD in order to compare any evidence of 
clustering. Additional objectives included explaining any differences stemming from the 
mapping based on known risk factors, and setting up a framework to facilitate easy mapping 
of any diseases covered in the Basse Health and Demographic Surveillance System (BHDSS) 
in the future.  
This thesis has been organized into distinct chapters which each begin with a short 
synopsis. This chapter provides a brief overview of the thesis and its objectives, in addition 
to describing the background of the study area.  
Chapter 2 reviews current literature on pneumonia and pneumococcal disease, such 
as causation, prevention, risk factors and burden of disease. It also includes relevant 
research on health geography and spatial analysis of disease. It concludes with a systematic 
review of studies pertaining to the distribution of pneumonia and IPD.  
Chapter 3 consists of the methods that were used to collect and analyse the data, 
including fieldwork, data extraction and statistical methods. Descriptions of the BHDSS as 
well as the Pneumococcal Surveillance Project (PSP) are included here.   
Chapter 4 presents the results of the study. All cluster analyses and statistical 
analyses are in this section, in addition to distribution maps.  
Chapter 5 is an interpretation of the study’s findings and comparison to results from 
previous research. This chapter also covers the strengths and weaknesses of the study as 
well as implications for further interventions.  











Gambia is a tiny West African country on the Atlantic Ocean, surrounded by Senegal 
on all land borders. Its namesake, the Gambia River, bisects the country into two, and is the 
focal point around which the country is based. The majority of the country is very flat 
running into the river, with some small hills in the east. With an area of only 11,295 km2, 
Gambia is the smallest country on the African continent. Its population is just under 2 
million, comprising several different ethnic groups including Mandinka, Fula, Wolof, Jola and 
Serahuli. The climate is hot and dry, with wet season from June to November [1]. See Table 
1 below for a brief overview of the country and its people.  
 
Table 1. Overview of Gambia [1, 2, 3, 4] 
Population 1,925,527 (July 2014 est.) 
Population under 15 745,841 (38.7%) 
Median age 20.2 years 
Population growth rate 2.23% 
Life expectancy  64.4 years 
Infant mortality rate 65.7 deaths/1,000 live births 
Population below poverty line 48.4% 
Access to clean water 90.1% 
Access to basic sanitation 60.2% 
Area 11, 295 km2 
Ethnic groups (%) Mandinka (42), Fula (18), Wolof (16), Jola 
(10), Serahuli (9), Other (5) 
Religion (%) Muslim (90), Christian (8), Other (2) 
Government Republic  
Health expenditure  4.4% of GDP 
Literacy rate (above 15) 51.1% 
HIV-1 infection 1% 
 
1.2 History 
Early Gambian history consists mostly of indigenous tribes, before its inclusion in the 
Malian Empire unified the region in the 14th century. European colonization of Gambia 
began in the 15th century, with Portuguese explorers taking advantage of the Gambia River, 
which allowed relatively easy access deep into the West African exterior. The British bought 
the trading rights from the Portuguese in order to maintain a colonial presence in the face 
of French supremacy in West Africa, and ran an extensive slave trade until abolishing slavery 
in Britain in the early 19th century. Despite this, slavery was not officially abolished in 
Gambia until the beginning of the 20th century. Gambia remained a British Colony up until 






Since its independence, Gambia has retained a close partnership with its neighbour 
Senegal, providing military, economic and political support. Due to the length and 
permeability of their shared border, there are many shared ethnic groups between the two 
countries. In 1981, rebels attempted to overthrow the government, but were defeated by 
the President, Sir Dawda Jawara, with aid from Senegalese forces. In an effort to restore 
confidence in the government, as well as aid the failing economy, Gambia and Senegal 
signed a Treaty of Confederation the next year, unifying the two countries in a close 
partnership. The Confederation was instrumental in facilitating stability to the region, and 
preventing black market cross-border trading from seriously damaging either national 
economy. Having achieved political stability once more, the pressing need for unification 
diminished, and within a few years, Gambia withdrew from the Confederation. President 
Jawara remained in power for another five years before the 1994 coup, led by the young 
lieutenant Yahya Jammeh, overthrew his government and established a military run regime. 
Jammeh began transitioning back to a democratic government, and resigned from the 
military to run for office as a civilian. Jammeh has won every subsequent election and 
remains in power today [5].  
 
1.4 Economy 
Gambia’s economy is heavily dependent on agriculture and tourism. Close to three 
quarters of the workforce remains closely involved in sustenance farming, mainly through 
crops such as groundnuts, various cereals (millet, sorghum, maize, rice) and raising livestock 
(cattle or goats). Fishing has not become a major industry although due to the size and 
shape of the country, or more specifically the river, the majority of the population has 
access to the water throughout the year. Tourism continues to play an important role, and 
offers mainly European travellers a close and safe option to explore the African continent. 
The abundance of native birdlife has become a serious draw, with people coming from all 
over the world to go bird watching [1].  
While many developing countries in Western Africa are infamous for high poverty 
rates, political volatility and disease, Gambia has enjoyed a relatively stable period of 
governance, which in turn has resulted in very few disruptions to social services, health 
services, and its economy. Perhaps because of this, many human aid and research 
organizations have set up operational bases in Gambia, including the Medical Research 
Council (MRC) of the United Kingdom. The MRC main compound is in Fajara, a suburb of the 
capital city Banjul, but there are also several field stations and research sites spread 
throughout the country. This thesis was based out of the field station in Basse Santa Su, the 







One notable disruption in Gambia’s current events was the 2014 Ebola crisis and its 
ongoing effects. In late 2013, an outbreak of Ebola virus spread through nearby Guinea, 
Liberia and Sierra Leone, as well as isolated cases in Senegal and Mali. Despite having no 
confirmed cases in Gambia, virtually all West African tourism plummeted, and Gambia saw a 
cancellation rate of 65% of bookings. The exact repercussions are unknown, and its effects 
may be seen for years afterwards, although Gambia remains Ebola free at the time of this 
thesis. However, given that a substantial portion of Gambia’s employment is derived from 
tourism, it is safe to say that the impact from this event will be substantial [6].  
 
1.6 Pneumococcal conjugate vaccines 
Gambia, along with several other Sub-Saharan countries, face a disproportionate 
amount of disease attributed to the pneumococcus bacteria [7]. Invasive pneumococcal 
disease in the region has been reported at up to 10 times the rates in industrialized 
countries [8], sparking a need for an intervention to protect against the pneumococcus. 
While there are several options when it comes to preventing the spread of pneumococcal 
disease (see Chapter 2), conjugate vaccines were chosen for their safety, immunogenicity, 
and ability to induce immunological memory in Gambian children [9].  
In 2009, the Gambian government introduced pneumococcal conjugate vaccines 
(PCV) into the routine vaccination schedule, which were shown to reduce childhood 
mortality in associated diseases. However, there was concern over the possibility of an 
emergence of non-vaccine serotypes in response to the introduction of PCVs into the 
population, and so a surveillance system was set up to monitor the results of the PCVs. This 
project is called the Basse Health and Demographic Surveillance System, and has been 
operating since 2007 out of the MRC Basse field station. The BHDSS comprises the southern 
part of the Upper River Region, consisting of everything south of the Gambia River. This area 
has only one major health centre, and five peripheral clinics providing inpatient and 
outpatient care, as well as referrals to the Basse Health Centre [10]. Figure 1 below shows 
the location of Gambia and the study area in relation to Africa, its West African neighbours, 
and within its own borders.  
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Figure 1. Map of African continent showing the relative location of Gambia with regards to 
the surrounding countries, as well as the study area within the Upper River Region.  
 
1.7 Aim of Thesis 
 The overall goal of this thesis was to map case data for IPD and RCP to identify any 
locational differences with the introduction of a pneumococcal conjugate vaccine. If any 
differences were observed, the focus would shift to attempt to explain these differences 
using other variables measured as part of the overarching project. Specifically, the before 
and after vaccine distributions were of particular interest, as they can provide a closer look 
into pneumococcal conjugate vaccines efficacy and effect on a population.  
 
1.8 Conclusion 
 Gambia has long since been considered an excellent place to conduct research for 
children’s health. Numerous studies have been undertaken in the region [11, 12, 13], and 
with the addition of a surveillance system to monitor the effect of pneumococcal conjugate 
vaccines, more are underway. This thesis makes use of the excellent pre-existing systems 
already in place in rural Gambia, from previous MRC studies, as well as building on current 
studies. The results from this particular study should identify areas of interest with regards 
to vaccine efficacy and geospatial distribution.  
6 
 
Chapter 2 - Literature Review 
 
 This chapter reviews previous literature to provide a background on topics discussed 
in this thesis.  Section 1-4 introduces pneumonia as a disease and covers causes, symptoms, 
diagnosis, treatment and risk factors. Section 5 covers vaccines and their effects, while 
section 6 discusses replacement carriage. Section 7 describes Invasive Pneumococcal 
Disease and its relation to pneumonia which is continued in section 8 with regards to 
disease in Gambia. Section 9-11 cover Geographic Information Systems and their uses, both 
inside and outside of Africa. Section 12 contains a systematic review of relevant studies that 
compared pneumonia or pneumococcal disease using GIS software.  
2.1 Pneumonia 
Pneumonia is a respiratory disease that has been plaguing humanity for centuries. 
Early Greeks recognised its symptoms, although its exact causes were unknown up until the 
end of the 19th century, when work by Klebs, Friedlander, and Frankel identified bacteria in 
pneumonia patients, sparking a new era of microbiology [14]. Its prevalence and mortality 
around the world earned it the moniker “the captain of the men of death” [15]. Today, 
pneumonia has been studied extensively, and although much more is known about the 
disease and its effects, there is still much work to be done as it continues to play a major 
role both in the global burden of disease.   
The term pneumonia describes a lower respiratory infection that primarily affects 
the lungs, by filling the alveoli with fluid, restricting the absorption of oxygen. It is relatively 
common, affecting 450 million people per year [16]. Luckily, the majority of these cases are 
mild, and require no more than a week or two for a full recovery. Pneumonia’s true impact 
on the global scale comes from its disproportionate effect on the young, elderly and those 
with compromised immune systems [17]. While respiratory infections on their own can be 
serious especially to at-risk demographics, when coupled with additional illnesses the end 
result can be fatal. Deaths from complications with pneumonia account for a serious 
proportion of elderly deaths, but in terms of DALY’s, childhood pneumonia is one of the 
most pressing illnesses in the modern era [18]. While childhood pneumonia only accounts 
for 2% of the childhood mortality rates in industrialized countries, it is responsible for up to 
20% in the developing world. If neonatal deaths are included, of which a significant 
proportion are related to pneumonia and sepsis, this statistic can reach as high as one third 
of total childhood mortality under the age of 5 [19]. This means that every year, 
approximately 156 million new cases of childhood pneumonia occur, with over 95% 
occurring in the developing world. Of these, approximately 2 million children will perish 
from the disease, making pneumonia the biggest single threat to childhood mortality [20]. 
Improvements in medicine and health management have reduced the overall mortality from 
4 million in the 1980’s, but there still remains work to be done [21]. With over 90% of the 
world’s children living in developing countries [22], this highlights the need for continued 
focus on the area of childhood respiratory illnesses [23]. 
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2.2 Streptococcus pneumoniae 
There are several different causes of pneumonia, including bacteria, viruses, fungi 
and parasites, although most cases originate from a few common bacteria and viruses. The 
most frequent type of bacteria is Streptococcus pneumoniae, which is isolated in 30-50% of 
all cases where a pathogen is identified, followed by Haemophilus influenzae type b, 
Staphylococcus aureus, and Klebsiellia pneumoniae [16]. The leading viral cause is the 
respiratory syncytial virus, found in 15-40% of viral cases, followed by influenza A and B, and 
adenovirus [24].  
While the many causes of pneumonia are all deserving of attention, the majority of 
the international focus remains on bacterial sources, namely Streptococcus pneumoniae, 
and to a lesser extent, Haemophilus influenzae. As these account for such a large portion of 
the serious cases of pneumonia, any interventions aimed at these bacteria are liable to have 
a large effect and reach the greatest number of people. Both of these causes are vaccine 
preventable, and there has been extensive work with vaccine development that is ongoing 
today [25]. For the purposes of this thesis, the focus from now on is on Streptococcus 
pneumoniae.  
Streptococcus pneumoniae is an encapsulated, alpha-hemolytic, Gram positive 
bacteria. It is normally found exclusively in the nasopharynx of humans, where it grows in 
short linear pairs or chains. It is commonly known as the pneumococcus. Transmission of 
the pneumococcus occurs through person-to-person routes, via direct oral contact, 
respiratory droplets, or indirect contact with respiratory secretions from an infected host 
[26]. The carrier remains communicable for as long as the pneumococcus is resident in the 
nasopharynx, either as short as a few days with antibiotic treatment, or virtually indefinitely 
if asymptomatic. The pneumococcus is increasingly being recognised for its role in 
polymicrobial diseases, notably in combination with Staphylococcus aureus. Polymicrobial 
diseases are caused by the interaction of multiple micro-organisms, and may help or hinder 
other microbes [58].  
The polysaccharide capsule that surrounds the pneumococcus comes in many 
different forms, each having unique virulence, prevalence, and drug resistance 
characteristics. These individual forms are classified as serotypes, and there have been 
almost 100 different serotypes that have been identified for pneumococcus to date [27]. 
The organism is incredibly widespread, with a large portion of healthy people carrying some 
strands asymptomatically throughout their life. This number varies throughout the world, 
with developing countries boasting much higher rates, although it can also be affected by 
other factors, particularly crowding and background status [28]. For the most part, many of 
these serotypes are relatively docile, and only a small portion make up the bulk of infectious 
pneumococcal cases. Serotypes can vary greatly according to the age and location of the 
patient, as well as seasonality [29].  In Bangladesh, serotypes 1, 5, 14, 18C, 19A and 38 
accounted for more than three quarters of total pneumococcal disease [30], while in 
Gambia, serotypes 1, 5, 6A, 14, 19A and 23F accounted for two thirds of the disease burden 
[31]. Studies in Latin America show differing proportions of serotypes isolated, with the 
most common by far being 14 (51.6%), followed by 6B and 19F just under 10% each [32].  
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2.3 Symptoms, diagnosis, and treatment 
 Due to the many pathogens that can lead to pneumonia, the exact list of symptoms 
is varied, although rusty coloured sputum is characteristic of infection by Streptococcus 
pneumoniae. High fevers and difficulty or rapid breathing are common across most causes, 
with indrawing of the chest occurring in severe cases. Cough, headaches, chills, lethargy, 
and a loss of appetite may be present, in addition to stridor and convulsions in infants. 
Malnutrition is considered a warning sign of severe pneumonia or severe disease if 
accompanied by difficult breathing. Breathing rates are variable depending on the patient 
age, and a raised rate is defined as 50 breaths or more per minute for 2 to 12 months, and 
40 breaths per minute for 12 to 60 months [19]. The WHO has recently revised its 
definitions of pneumonia from three categories to two, which allows for easier diagnosis, 
treatment, and support, especially in resource poor areas or those with difficulty accessing 
healthcare [21].  
Diagnosis of pneumonia depends on the resources on hand at the time. As the 
majority of suspected pneumonia cases occur in the developing world, adequate diagnostic 
facilities are not always available. Ideally, a chest radiograph is considered the gold 
standard, although there is debate over the correct, or at least consistent interpretation of 
X-rays [33]. Guidelines for interpretation are provided by the WHO, but a degree of error 
still exists. Microbial testing of the sputum or other biological sample is another common 
diagnostic method, which provides an added benefit of identifying the pathogenic agent, 
although it too comes with its own problems namely an accessible laboratory and an 
adequate sample [34]. Polymerase chain reactions have also shown to be quite effective 
particularly at isolating respiratory syncytial viruses [35].  
Streptococcus pneumoniae is susceptible to antibiotics, which remains the primary 
method of treatment. The exact type of antibiotic is dependent on serotype, region and 
health status of the patient, although antibiotic resistant strains are becoming more 
widespread in recent years due to over-prescription and improper use of antibiotics [36]. 
Current recommendations for treatment of pneumonia include amoxicillin, penicillin, 
gentamicin, or ceftriaxone, depending on the age of the patient, severity and any underlying 
regional diseases such as HIV [21]. Early diagnosis remains one of the most important 
factors for survival, which requires recognition by caregivers of key warning signs in 
children.  
 
2.4 Risk factors 
As with any disease, the best medicine is prevention, and there are several factors 
that have shown to put children at greater risk of catching pneumonia. These risk factors 
can be grouped into definite, likely, or possible risks, based on the availability of evidence to 
support them. Definite risk factors include malnutrition, low birth weight, non-exclusive 
breastfeeding during the first 4 months, not receiving measles immunisation in the first 12 
months, indoor air pollution and crowding [37, 38, 39]. Likely risk factors include parental 
smoking, zinc deficiency, caregiver experience and concomitant diseases (diarrhoea, 
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asthma, etc.) [40, 41, 42]. Possible risk factors are not yet fully understood, but it is thought 
there could be a link between pneumonia and the following: mother’s education, day-care 
attendance, humidity, altitude, temperature, Vitamin A deficiency, birth order and outdoor 
air pollution [16].   
In addition to the risk factors listed above, age is a very well known risk factor for 
many types of respiratory diseases, with young children bearing the brunt of this burden. In 
particular, 93% of infants in Gambia were shown to have been colonized with 
pneumococcus by one month in age [43]. Even in developed countries, carriage of 
pneumococcus increased from just over 8% of infants at 1.5 months, to just under 50% at 14 
months [44]. Adults tend to have a greater presence of antibodies to pneumococci, 
suggesting that age is a surrogate marker for naturally acquired immunity [45]. Younger 
children have had less time to build up any resistance to invading pneumococci, and as a 
result, are disproportionately affected [46].  
 
2.5 Vaccines 
At the beginning of the 20th century, the heavy burden of pneumonia called for 
better medical treatment than simply sending the patient out of the city for “clean air.” 
Advances in microbiology had identified different serotypes of Streptococcus pneumoniae, 
and the first pneumococcal polysaccharide vaccine (PPSV) was developed in the late 1920s 
[36]. The first PPSV only protected against a single strain of pneumococcus, and efforts to 
improve the vaccine led to the creation of a tetravalent PPSV in the mid-1940s [47]. Despite 
moderate success, the vaccine was a victim of unfortunate timing as it coincided with the 
discovery of penicillin. An explosion of interest in the promising field of antibiotics led to 
pneumococcal vaccination programs being left to the wayside, where they remained 
virtually untouched for several decades until the first strains of antibiotic-resistant bacteria 
started appearing, sparking a revitalised surge in interest [48].   
Increasing antibiotic resistance hastened a revival of the pneumococcal 
polysaccharide vaccines, and due to advances in technology and medicinal research, the 
next PPSV had the 14 most common serotypes in it. The most recent version of the PPSV 
covers 23 serotypes, and is marketed towards the elderly population. Despite the coverage 
afforded by polysaccharide vaccines, they remain ineffective in children under 2 years old. 
As this is the population most heavily affected by the burden of pneumococcal disease, a 
new solution was needed. Pneumococcal conjugate vaccines (PCV) work by attaching the 
polysaccharide capsule antigens to a diphtheria toxoid, which allows for a greater immune 
response in all age groups. Modelled on the successful Haemophilus influenza type B 
vaccine [49], the pneumococcal conjugate vaccine was first produced to protect against the 
7 most harmful serotypes (4, 6B, 9V, 14, 18C, 19F and 23F). PCV-7 was widely distributed 
around the world, and has enjoyed success particularly in developing countries where the 
burden of pneumococcal disease is high. Additional serotypes were added to the vaccine, 
and its current form has 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). 
Implementation of PCV-13, and its competitors predecessor, PCV-10, has been widely well 
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received, having been coupled with catch up immunization programs around the globe [50, 
51, 52].  
 
2.6 Replacement  
 In addition to issues arising as a result of incomplete coverage, and therefore a lack 
of acquired protection against any serotypes, vaccinated people are at risk for 
nasopharyngeal replacement. By eliminating the most common serotypes, this leaves the 
Streptococcus pneumoniae friendly environment of the nasopharynx available for 
colonization by other less common serotypes not covered in the PCV [53]. Alternatively, 
replacement could simply be a result of revealing underlying serotypes, which due to their 
scarcity, are not usually picked up during regular testing [54]. The uncertainty around this 
point raises questions as to whether PCV are an effective way to deal with pneumococcal 
disease, since replacement with more dangerous serotypes could leave a population worse 
off than the original colonisation not been tampered with. In addition, allowing rarer 
serotypes space to flourish, could lead to outbreaks of new strains of pneumococcal disease. 
While the overall consensus of PCV is a positive one, vaccination programmes are still tightly 
monitored in order to assess any potential harm that may arise, mainly due to replacement 
carriage. There are several studies looking into the effect of replacement, especially with 
regards to the introduction to PCVs, which are being brought into place all over the world 
[43, 55, 56, 57]. As mentioned previously, this replacement phenomenon is not exclusive to 
Streptococcus pneumoniae, and there is strong supporting evidence that the pneumococcus 
has an inverse relationship with Staphylococcus aureus [58]. While a complete 
understanding of the exact interactions between Streptococcus pneumoniae and the 
multitude of other microbes in circulation is not possible, any actions taken to reduce 
pneumococcus prevalence must be carefully considered as they may have further reaching 
effects than originally anticipated.  
 
2.7 Invasive Pneumococcal Disease 
In addition to affecting the alveoli of the lungs, Streptococcus pneumoniae can 
migrate from the respiratory system into other bodily systems, causing serious illnesses. The 
spread of the pneumococcus into a normally sterile bodily fluid, such as blood or 
cerebrospinal fluid (CSF), is known as invasive pneumococcal disease (IPD), which is a 
considerable burden to children around the world. Bacteraemic pneumonia is the most 
common form of IPD, followed by meningitis and septicaemia. The exact mechanism by 
which the pneumococcus is translocated to a sterile site is not yet fully understood, but it 
often occurs in the presence of coexisting conditions such as pulmonary infections [59, 60]. 
Risk factors for IPD are similar to those mentioned above, in addition to CSF leaking, chronic 
organ disease in adults, HIV infection, decreased immune function, and functional or 
anatomic asplenia [36]. Cochlear implants have also been shown to increase the risk of both 
IPD and acute otitis media (AOM), a common form of pneumococcal infection in young 
children. In addition to this, certain ethnic groups have proved to be more susceptible to IPD 
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than others, with American First Nations and Australian Aboriginal populations showing 
much higher rates than might be expected [36].  
Meningitis is an infection of the membranes surrounding the brain, known as 
meninges. Like pneumonia, it has a plethora of pathogenic causes including parasitic, fungal, 
and viral, but the majority of cases are caused by bacteria. In particular, Streptococcus 
pneumoniae is the leading cause of meningitis among children under the age of 5 [61]. 
Bacterial meningitis is almost always fatal if left untreated, and accounts for a significant 
proportion of meningitis deaths annually [62]. Non-fatal cases can often result in permanent 
disability, which can play a huge impact on quality of life. In 2013, an estimated 300,000 
people died from meningitis, the majority of which lived in the developing world [63]. 
Outbreaks of meningitis tend to be reasonably isolated around the world, with sporadic 
cases throughout the industrialized nations, with the exception of Sub-Saharan Africa [64]. 
Symptoms include neck stiffness, impaired/altered mental behaviour, and a fever. A bulging 
fontanelle may also be present in young infants.  
Septicaemia is commonly known as blood poisoning, and as the name suggests, 
occurs when bacteria get into the bloodstream, causing an immunological inflammatory 
response in an effort to protect itself. Pneumococcal septicaemia damages red blood cells in 
the bloodstream, which are then unable to properly transport enough oxygen to the 
surrounding tissue, resulting in oxygen deprived vital organs, which can be fatal even when 
treated [65].  
 
2.8 Pneumonia in Gambia 
 Gambia, like many other sub-Saharan countries, is particularly susceptible to 
pneumonia and invasive pneumococcal disease, and it has rates far outweighing developed 
countries [66]. Unlike its neighbours however, it is a hotspot for pneumococcal research, 
and continues to produce large quantities of research on pneumonia [67]. Various projects 
monitor the state of nasopharyngeal carriage [53], the effects of pneumococcal conjugate 
vaccines [68], molecular etiology [69] and pneumococcal risk factors [70]. Ongoing projects 
such as the Pneumonia Etiology Research for Child Health (P.E.R.C.H.) project and the 
Pneumococcal Surveillance Project (PSP), both funded by the Bill and Melinda Gates 
Foundation, are large, multi-component studies that are at the forefront of pneumococcal 
and pneumonia research in the world [71, 72].  
 
2.9 Geographic Information Systems 
The field of health geography has been around for centuries, although it has not 
always been known by this name. Tracking the spread of a disease is a core tenement of 
epidemiology, and efforts to “map” particular diseases by their incidence rates has led to 
many breakthroughs in disease management. Perhaps the most famous example is John 
Snow’s use of maps to identify a common spatial feature between cholera patients in the 
1850s, in this case, a contaminated water pump. By mapping some basic demographic 
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information, he was able to produce a Geographic Information System (GIS) that was then 
put to use identifying and preventing the problem. Snow’s GIS might be crude by today’s 
standard, but the overall goal has not changed.  
 Both infectious and non-communicable diseases are often related in many aspects, 
particularly with regard to location. While infectious diseases share transmission vectors 
(and by virtue of most transmission vectors, a moderate degree of relatedness regarding 
geography), non-communicable diseases can have a multitude of environmental and spatial 
risk factors based on locations that are possible to identify and predict disease incidence. 
Addressing even a single health related variable can be complicated enough, and as we have 
come to realize health, or lack thereof, is a multi-factorial issue requiring a holistic approach 
in its dealings. GIS programs allow multiple variables to be analysed simultaneously, which 
permits a more complete picture of health to be produced [73].  
 
2.10 Applications of GIS software 
Modern geographic information systems are all computer programs that allow for 
digital mapping and analysis directly within the program itself. While originally designed by 
Roger Tomlinson for computer mapping of land usage, the capabilities of the programs soon 
exceeded their intended purposes, and the concept was quickly adapted to fit many other 
needs [74]. As computers became more powerful and widely accessible, so too did GIS 
usage, and now it features to some extent in virtually all urban planning, public health 
policy, resource management, and more.  
 GIS software can be applied to infectious disease outbreaks as well as public health 
epidemics, as shown in the following example. In 2008, Nygard et al. describe the case study 
of an outbreak of Legionnaires’ disease in Norway in 2005. Public health officials were 
unable to determine any similarities between the cases, all of whom were spread over a 
wide location, with no places visited in common between them. Upon mapping the cases 
and the region into a GIS program however, it was noted that all cases lived within a 1 
kilometre radius of an industrial air scrubber, which was infected with the bacteria, and 
distributing infected particulate matter. The GIS was able to coordinate and analyse all case 
movement for the time period, places of residence, weather data, as well as environmental 
details and feature locations [75].  
 
2.11 GIS in Africa 
The advantages of GIS applications should be immediately recognisable, and it 
should come as no surprise that its usage is already commonplace in developed countries. 
Developing countries are often left to the wayside, despite having a significant portion of 
infectious disease and standing to benefit the most from improved disease management. 
Three of the main diseases studied in Africa that rely on GIS technology are tuberculosis 
(TB), HIV/AIDS and malaria. All of these diseases rely on different transmission vectors to 
spread (respiratory droplets, sexual contact and mosquitoes respectively), all of which can 
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be easily represented in a GIS. Touray et al. showed evidence of significant TB clustering in 
Gambia [76], while Randremanana et al. showed contributing factors which increased the 
risk of significant TB clusters [77]. With TB relying on close proximity for spread, having the 
capability to analyse clusters and distribution rates is invaluable.  
HIV/AIDS interventions can be costly and resource intensive, therefore identifying 
“hotspots” and “coldspots” can allow for more effective programs. Zulu et al. produced a 
large study on HIV/AIDS in Malawi which examined risk factors affecting prevalence using 
spatial analysis and clusters to predict where interventions would have the greatest impact 
[78]. Messina et al. showed similar results in the Democratic Republic of Congo, a region 
that has been hard hit by the epidemic [79]. 
Climatic models and ecological features can play a role in many diseases, but 
nowhere are they more apt than in malaria studies, due to the direct effects on the 
transmission vector. A study by Omumbo et al. showed malaria intensity could be predicted 
using high-resolution risk maps created using basic geographic information and 
epidemiologic case data [80]. Carrin et al. take the prediction rates a step further, and show 
how to apply them to a policy level, with respect to tourism, resource management and 
infrastructure development [81].  
While the previous examples are only a small portion of current studies intended to 
provide context on ways to incorporate GIS into research, there are many others. With the 
rapid emergence of new computing technology and with more recognition being given to 
the usefulness of GIS, the field is expanding exponentially, and new and old projects are 
adding GIS into their toolbox of analysis methods [82]. The scarcity of qualified staff is 
currently a hurdle for GIS in Africa, in addition to suitable spatial datasets [83]. Both of these 
were easily dealt with in this thesis owing to the pre-existing and comprehensive spatial 
mapping of the study region by my supervisor, who was then able to provide expert support 













2.12 Systematic Review 
 
2.12.1 Objective 
- To identify and describe any recent studies that have examined the spatial 
relationship between invasive pneumococcal disease cases and radiologically 
confirmed pneumonia cases, in particular the geographic and temporal locations of 
individual cases. 
- From these relevant studies, identify any key factors that may explain the geographic 
location of cases of invasive pneumococcal disease or radiologically confirmed 
pneumonia.  
 
2.12.2 Search strategy for systematic review 
In order to fully understand the depth and magnitude of current research on the 
spatial mapping of pneumococcal disease and radiologic pneumonia, a systematic literature 
review was undertaken. The original objectives of the review were to identify and focus on 
studies that described the spatial relationship between invasive pneumococcal disease and 
radiologically confirmed pneumonia with regards to geographic and temporal locations of 
individual cases. Despite numerous studies examining similar topics (geographical location 
of pneumonia cases, spread of pneumococcal disease, serotype distribution, etc.) no studies 
were found to examine the direct spatial relationship between invasive pneumococcal 
disease and radiologic pneumonia. The objectives were then changed to focus on any 
studies that looked at factors affecting geospatial distribution of invasive pneumococcal 
disease or radiologically confirmed pneumonia. As the research in Gambia is mainly aimed 
at children’s health, so too was this review, which included studies based specifically for 
children where possible, or that included children as part of the analysis. To the best of my 
knowledge, this makes our study the first to compare these two diseases directly using 
spatial analyses.  
A thorough review of the available literature was completed by searching PUBMED, 
Scopus and Science Direct electronic databases. Using Boolean connectors, the following 
search terms were used to identify relevant studies: “pneumonia”, “invasive pneumococcal 
disease”, “pneumococc**”, “Streptococcus pneumonia*”, “IPD”, “spatial analysis”, 
“geospatial”, “mapping”, “geographic information system*”, “GIS”, “clustering” and 
“distribution”. Varying combinations of these terms were combined to include at least one 
(usually several) of both the pneumococcal and the geospatial areas. Search terms were 
limited to published, peer-reviewed articles after 1950. Due to the relatively recent 
emergence of GIS technology, no appropriate studies were found before 1990, and later 
searches were amended to help filter irrelevant studies out. A total of 656 studies were 
identified within these search criteria, which included 216 duplicates, or 440 unique studies. 
In addition, a search of grey literature and referenced papers turned up one additional 
paper through direct correspondence with the author. Exclusion criteria were applied to 
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these 441, which removed studies focusing on serotype distribution, non-human subjects, 
or proteomics. 34 studies were identified from this list, which had their abstract and title 
printed for manual review. 9 articles were selected as appropriate to this review (See Figure 
2). All studies had a primary endpoint of pneumonia (radiologically confirmed or other), or 
invasive pneumococcal disease, which were then displayed using some form of GIS to 













2.12.3 Introduction to selected studies 
A brief summary of each study is provided below, while characteristics of different 
studies are described in Table 2-5.  The majority (8/9) used hospitalisations as a primary end 
point, with the last using child mortality. The studies come from all across the globe, with 
three in Brazil, two in Canada, one in the United States, one in New Zealand, one in England, 
and one in Bangladesh. The two Canadian articles were from the same study, although while 
the first analysed the spatial distribution of determinants, the second looked solely at 
hospitalisation rates. The data from all studies were collected from 1988 to 2011 and 
reported from 2001 to 2014. This relatively late development into spatial modelling is owed 
mainly to the recent usage of Geographic Information Systems, which started becoming 
commonplace in the early 1990s. Advances in GIS accessibility and availability have reduced 
the difficulty of computing spatial analysis, which has allowed more complex analyses to 
occur in more studies.  
Ali et al. (2001) examined the effects of community interventions in children under 
the age of two. Community health workers received additional training for identification, 
treatment and management of pneumonia, in addition to a specialised Acute Lower 
Respiratory Illness centre being set up in the study hospital. The project aimed to identify 
not only the different rates between the intervention and control groups, but also various 
access-to-care factors, such as distance to the nearest health centre, density of allopathic 
and indigenous practitioners and population density. Risk maps were created based on 
mortality rates, identifying regions that warranted interventions. The authors acknowledge 
the role of environmental characteristics that might have influenced the results, but were 
unable to address any of these without further resources and technology [84].  
In 2004, Andrade et al. examined the spatial distribution of radiologically confirmed 
pneumonia cases in an urban environment in Brazil. Using census data to identify household 
income, and tracking notified cases through home visits, the authors looked at the 
relationship between socioeconomic status and incidence rates of pneumonia. Andrade et 
al. also conducted a hotspot analysis to identify potential hotspots of pneumonia, showing 
one most likely cluster with one other secondary cluster. The authors also used a “nearest 
neighbour” approach to locate significant clusters that crossed local administrative borders, 
allowing for more inclusive interventions [85].  
Crighton et al. (2007) produced a county-wide retrospective study on the 
hospitalisation rates from pneumonia in the Canadian province of Ontario. All age groups 
were included across all 49 counties in the province, which ranged in size from 13,000 to 2.5 
million, for a total of 12 million. By searching through the Canadian Institute for Health 
Information, they found nearly a quarter of a million cases who had been discharged from a 
hospital with a diagnosis of pneumonia or influenza. They note that pneumonia on its own 
has low specificity when using the CIHI database, but that by aggregating the data with 
influenza, it can reliably identify approximately 80% [86]. Various physical, social and 
economic, environmental, behavioural and healthcare related variables were obtained from 
several national databases (Ontario Health Survey, Environment Canada, Canadian Census, 
Ontario Health Insurance Program and the Canadian Physician Database) [87].  
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The second study produced by the same authors was published in 2008 and instead 
looked at the direct spatial relationship between the cases themselves, rather than the 
determinants. The same sample data was used, with 241,803 hospitalisations from a 
background of 12 million inhabitants. As with the previous study, the findings were limited 
by the lack of specific aetiology for pneumonia diagnosis [88].  
In Brazil, Mukai et al. (2009) looked at hospitalisation rates in infants under one year 
of age. Using a spatial point analysis technique, they calculated a spatial autocorrelation of 
hospitalisation rates and incidence rates. The study then used these rates to create a box 
map diagram which classified all the cities into four categories depending not only on their 
own rates, but also their neighbour’s. Mukai et al. make note of the effect of geography (in 
this case, local mountain ranges), which defy current health administrative borders, making 
cohesive interventions difficult. Cases in this study were not radiologically confirmed using 
any standard diagnostic tool, but rather based on clinical assessment which is subject to 
variation. In addition, patients were excluded if they attended private hospitals, or were 
treated in outpatients, which does not provide a complete picture of the true burden of 
pneumococcal disease [89].  
In 2011, a group of authors (Thorn et al.) from the 2004 study [85] produced a 
second report, again on clustering of pneumonia cases in urban cities in Brazil. The city 
population had grown by 200,000 residents, and they showed a much higher incidence rate 
among children under the age of three compared the previous study. The four-fold increase 
in rates was due to an increase in sensitivity with regards to inclusion criteria, as well as 
broadening the case recruitment areas (hospitalisations vs hospitalisations, outpatients, 
health clinics, etc.). Pneumococcal vaccines had not yet been implemented as part of Brazil’s 
national health program, and so rates of PCV coverage were quite low. They conducted a 
hotspot analysis again, which showed the same regions were at risk, despite a difference of 
roughly 7 years. However, the cases have become more spread out, perhaps due to the 
inclusion criteria. Pneumonia rates were once again inversely linked to socioeconomic 
status, with the highest incidence rates being found in the very poor regions [90].  
In a study by Feemster et al. (2013), they investigated the relationships between 
neighbourhoods in an urban area in Philadelphia, USA. Socioeconomic status was 
significantly associated with an inverse amount of pneumococcal disease, with higher 
average income resulting in fewer cases compared to more cases with low average incomes. 
The authors calculated relative risks for increased density, percentage of the population 
black, percentage of the population <5 years, and percentage of the population <65, all of 
which showed significant adjusted relative risks, and did not include the null hypothesis 
after adjusting for confounding variables. Contrary to other studies on risk factors [91], the 
household size (an indicator of crowding) was not significantly associated with 
pneumococcal disease [92].  
Unlike the other studies listed here, Pearson et al. (2013) examined the spatial 
distribution of pneumococcal pneumonia as the result of a specific incident, namely a 
natural disaster. Beginning in 2010, the New Zealand city of Christchurch has undergone a 
significant period of seismic activity culminating in a major event in February 2011. During 
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severe earthquakes, a phenomenon known as liquefaction occurred, which loosens 
saturated soil particles and ejects a fine particulate matter into the air. It is well known that 
particulate matter can increased the risk of lung infections, but a recent article [93] reports 
finding evidence of Streptococcus pneumoniae bacteria on particulates as small as 0.55 um 
in size. Unlike the slower, human-based transmission route, ejected airborne particles can 
spread very quickly and are subject to environmental factors that offer a much broader, 
dispersal rate particularly compared to pneumococcal disease, which tends to favour a 
much closer transmission approach. The authors then used a space-time analysis to identify 
hotspot clusters across all cases. Purely spatial clusters were detected pre-earthquake which 
were significantly related to deprivation rates, and did not vary significantly post-quake. 
Fully adjusted spatio-temporal models did show a movement of clusters towards the 
southeast of the city, as well as an increase in relative risks in the central clusters. The 
authors acknowledge that not all clusters appear to be a direct result of the earthquake, but 
that due to the significant correlation with deprivation levels and a geographic shift in 
cluster locations, pneumococcal disease may be exacerbated by ejected particulate matter 
[94].  
Blain et al. (2014) look at the spatial variation in pneumonia and empyema 
hospitalisations in the North East England to examine the relationship between 
socioeconomic deprivation levels. The majority of cases came from large urbanized centres, 
while the rural distracts had the lowest risk. The authors identified covariate factors 
affecting the variation as deprivation, Child Wellbeing Index (CWI) score, number of 
neighbouring children requiring governmental support, and distance to the nearest health 
facility. This agrees with many of the previous studies that low socioeconomic status, or 
poverty, is significantly associated with poor health outcomes relating to respiratory 
infections, specifically pneumonia. The CWI scores and assistance programs were unique to 
this study and were not measured by other articles in this review, which offers a different 







Table 2. Tabulated Results from Systematic Literature Review (1/4).  
Study Authors Year Data collected Location Study population Cases/Outcomes 
A M. Ali, M. Emch, F.Tofail, A.H. Baqui 2001 1988 - 1993 Matlab, Bangladesh (rural) 78,272 children <2 
years 
791 deaths in children <2 years recorded for study 
period. 
B A.L. Andrade, S.A. Silva, C.M. Martelli, 
R.M. Oliveira, O.L. Morais Neto, J.B. 
Siqueira, L.K. Melo, J.L. Di Fabio 
2004 May 2000 – 
August 2001 
Goiania, Brazil (urban) 90,576 children <5 
years 
724 radiologically confirmed cases of pneumonia.  
C E.J. Crighton, S.J. Elliott, R. 
Moineddin, P. Kanaroglou, R. Upshur 
2007 April 1992 – 
March 2001 
Ontario, Canada (varied) Approx. 12,000,000 all 
ages 
241,803 discharge diagnosis of pneumonia and 
influenza.  
D E.J. Crighton, S.J. Elliott, P. 
Kanaroglou, R. Moineddin, R. Upshur 
2008 April 1992 – 
March 2001 
Ontario, Canada (varied) Approx. 12,000,000 all 
ages 
241,803 discharge diagnosis of pneumonia and 
influenza. 
E A.O. Mukai, K.S. Alves, L.F. 
Nascimento 
2009 2004 – 2005 Vale do Paraiba, Brazil 
(varied) 
63,766 children <1 
year 
2,227 hospitalised pneumonia cases.  
F L.K. Thorn, R. Minamisava, S.S. 
Nouer, L.H. Ribeiro, A.L. Andrade 
2011 May 2007 – May 
2009 
Goiania, Brazil (urban) 51,279 children <4 
years 
11,521 clinical diagnosis of pneumonia.  
3,955 radiologically confirmed cases, 3867 of 
which had geocoded addresses for inclusion. 
G K.A. Feemster, Y. Li, A.R. Localio, J. 
Shults, P.H. Edelstein, E. Lautenbach, 
T. Smith, J. Metlay 
2013 2005 – 2008 Philadelphia, United States 
(urban) 
3,849,071 all ages  1,422 hospitalised pneumonia cases.  
H A.L. Pearson, S. Kingham, P. Mitchell, 
P. Apparicio 
2013 October 2008 – 
December 2011 
Christchurch, New Zealand 
(urban) 
Approx. 350,000 all 
ages 
97 pneumonia cases notified.  
I A.P. Blain, M.F. Thomas, M.D.F. 
Shirley, C. Simmister, M.A. Elemraid, 
R. Gorton, M.S. Pearce, J.E. Clark, S.P. 
Rushton, D.A. Spencer 
2014 May 1997 – April 
2007 
Northeast England, United 
Kingdom (varied) 
462,900 children <14 
years 




Table 3. Tabulated Results from Systematic Literature Review (2/4).  
Study Case selection Weaknesses  Strengths  Funding  
A Active (scheduled in-house visits) and passive 
(outpatient clinics) screening in the Matlab 
Demographic Surveillance System.  
Not specific to pneumonia. Use of 
spatial filtering (blurs outliers and 
assumes continuous disease) 
Long, pre-existing data 
collection program.  
International Centre for Diarrhoeal Disease Research, 
Bangladesh (funded through various national aid 
agencies, including UNICEF. 
B Active (home visits) and passive (outpatient 
clinics and public/private hospital admissions).  
Case selection based on hospital 
responders.  
Feasible case criteria routinely 
applied allows for externally 
valid results. Combined 
analysis using smoothing and 
spatial statistics. 
Division of Vaccines and Immunization of the Pan 
American Health Organization, WHO, Bill and Melinda 
Gates Children’s Vaccine Program, Brazilian National 
Research Council, and the Goiania Municipal Health 
Secretariat.  
C Retroactive use of Canadian Institute for Health 
Information (CIHI) which monitors inpatient 
discharges.  
Not specific to bacterial 
pneumonia. Case selection based 
on hospital responders.  
Modern data identification 
system able to deal with large 
case numbers. 
Not listed.  
D Retroactive use of Canadian Institute for Health 
Information (CIHI) which monitors inpatient 
discharges. 
Ecologic study – difficult to draw 
conclusions at an individual level.  
Multilevel modelling allows for 
comparisons of multiple factors 
and their hierarchical order.  
Not listed.  
E Retroactively obtained from DATASUS (trans. 
Information Technology Department of the 
Brazilian Unified Health Care System) 
Cases confirmed by clinician and 
may not be subjective (x-ray). 
Excluded outpatient cases.  
Using own boundaries found 
new findings previous 
administrative ones had not.  
FAPESP (trans. Foundation for the Support of Research 
in the State of Sao Paulo).  
F Prospective clinical enrolment from outpatients 
or emergency rooms by paediatricians as part of 
the LEAP study.  
Self-reported variables. Using 
hospitalisations as proxy for 
serious disease. Ecologic study.  
Very high reporting and 
geocoding of all results (98%). 
Robust spatial analysis. 
National Council for Scientific and Technological 
Development, Brazil, and Pfizer.  
G Prospective clinical enrolment from 
hospitalisations in the five-county Philadelphia 
metropolitan region.  
Only pneumococcal bacteraemia 
patients included. No comparison 
between individual and 
community level factors.  
Mixed effect model accounts 
for small-scale variations in 
invasive pneumococcal disease.  
National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, and the Pennsylvania 
State Department of Health.  
H Retroactively taken from notifiable disease 
database (EpiSurv).  
No background air quality 
monitoring. Very small case 
numbers. Liquefaction data not 
continuous. 
Unique hypothesis with reliable 
clustering methods. Notifiable 
disease, so high degree of 
accuracy in population.  
Not listed. 
I Retroactively obtained from Hospital Episode 
Statistics (HES) database which monitors all 
hospital admissions to National Health Service 
hospitals in England.  
Ecological study – making 
assumptions of individuals using 
area population specific factors.  
Use of childhood deprivation 
measurements for the first 
time. Well-validated statistical 
methods, and comprehensive 
dataset.  
Not listed. 
- UK ESPE study funded by Glaxo Smith Kline 
Pharmaceuticals and Wyeth Pharmaceuticals 
- Two authors received grants from GSK 
Pharmaceuticals and Wyeth Pharmaceuticals.  
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Table 4. Tabulated Results from Systematic Literature Review (3/4). 
Study GIS Platform/Spatial Data Collection Case Criteria 
A ArcInfo and Atlas GIS used. Data taken from 
part of Matlab Surveillance System.  
No pneumonia: cough and/or low grade fever 
Pneumonia: respiratory rate more than 50 breaths per minute, no chest retractions or signs of severe disease.  
Severe pneumonia: Chest retractions or other signs of severe disease plus respiratory rates higher than 50 breaths a minute. 
Any cases below 2 months old were treated as severe pneumonia.  
B ArcView 3.2 GIS used. Digital map built from 
recent census, or else handheld GPS units used 
to geocode any additional cases.  
Clinical diagnosis of pneumonia then referred to radiologist for chest X-ray according to WHO standards.  
C ArcView 3.3 GIS and Geoda 9.5. Data taken from 
Statistics Canada and 1996 Census.  
Identified from CIHI Discharge Abstract Database. Discharged from hospital with a principal discharge diagnosis of pneumonia 
or influenza (ICD-9-CM code: 480 – 487). 
D ArcView 3.3 GIS and Geoda 9.5. Data taken from 
Statistics Canada and 1996 Census. 
Identified from CIHI Discharge Abstract Database. Discharged from hospital with a principal discharge diagnosis of pneumonia 
or influenza (ICD-9-CM, code: 480 – 487). 
E TerraView 3.2. Data taken from Regional Health 
Department of Taubate.  
Identified from Information Technology Department of the Brazilian Unified Health Care System. No further information 
provided.  
F ArcView 3.2 and SIGGO 2.0. Data taken from 
Data Processing Division of the Municipality of 
Goiania.  
Cases screened by consultant paediatricians for children aged 28 days to 36 months who presented with temperatures ≥39.0°C 
and/or suspicion of pneumonia or other pneumococcal disease (based on WHO guidelines of fast breathing and/or coughing). 
Blood samples were taken, and cases were confirmed with a radiologist’s assessment of a chest X-ray, taken upon enrolment.  
 
G ArcView 9.2 and StreetMaps USA. Data taken 
from hospital records, or telephone interview 
follow-ups.  
Hospitalised patients who tested positive for Streptococcus pneumoniae in at least one blood culture within 48 hours of 
admission. Blood cultures were initially performed by individual hospitals, and later confirmed by the central laboratory at the 
University of Pennsylvania.  
H ArcGIS 10.0. Data taken from notifiable disease 
records.  
 Cases identified from Notifiable Disease Report, which were then laboratory confirmed with a specific diagnosis of 
pneumococcal pneumonia. Non-specific cases of Invasive Pneumococcal Disease were excluded.  
I WinBUGS 1.14. Data taken from 2001 UK 
Census and converted using GeoConvert online 
tool.  




Table 5. Tabulated Results from Systematic Literature Review (4/4). 
Study Results Conclusions 
A  Highly significant differences between intervention and comparison groups in terms of death rates (6.82 vs 
11.82/1000, p<0.0001), allopathic practitioner/population rates (0.89 vs 0.5/1000, p<0.0001), population of 
households/baris (34.7 vs 32.7, p≤0.001) and population density around baris (3638 vs 4123/km2, p<0.0001). Overall, 
54% lower mortality rates with interventions.  
Community-based health interventions are effective by 
eliminating effects of other (socioeconomic) risk factors 
of acute lower respiratory infections (pneumonia).  
B Incidence rates (per 100,000) increased inversely with income areas: High = 242.5 (CI: 143.6-385.2), Middle = 748.0 (CI: 
657.5-847.4), Low = 879.1 (CI: 767.3-1,002.7), Very low = 919.3 (CI: 812.6-1,036.2). X2 trend: 23.1, p<0.001. Significant 
clusters detected with RR = 2.1, p<0.01 
Non-random distribution (clustering) of pneumonia 
cases occurring in crowded areas with low 
socioeconomic conditions.  
C Comparative Hospitalisation Quotients (CHQ) determined to be primarily affected by three variables: Aboriginal 
ethnicity (p=0.002), Low education (p<0.001) and heavy drinking (p=0.047). Moderate, yet significant degree of 
clustering for both males (Moran’s I=0.173, p<0.044) and females (Moran’s I=0.242, p<0.015), mainly in northern 
(rural) areas.  
Non-random distribution of pneumonia cases occurring 
in rural areas, noted for low education, heavy drinking 
and a larger proportional Aboriginal population.  
D Significant variation between county rates (14 to 56/100,000). Significant spatial autocorrelation between counties 
with high incidence rates (Moran’s I=0.186, p=0.023) when adjusted for age and gender. Consistent and significant 
effects from seasonality was found in 48 out of 49 counties (98%), with spatial autocorrelation occurring during the 
seasonal peaks May and June (Moran’s I=0.308 and 0.295 respectively).  
Similar to sister study (C), non-random distribution of 
pneumonia cases occurred in rural areas, with 
fluctuating rates throughout the year, corresponding 
with seasonal patterns of disease.  
E Significant spatial autocorrelation between regions (Moran’s I=0.37, p=0.02). Distribution of high hospitalisation rates 
(40.1-137.2 cases/1,000 live births) clustered around 8 cities which classified as high-high (high rates and high 
neighbouring rates), marking a clear area for interventions.  
Non-random distribution of pneumonia cases were 
identified, several of which crossed administrative 
divisions that had not previously been identified.  
F Mean annual incidence rates (per 100,000) of radiologic pneumonia were inversely associated with socioeconomic 
status. High SES = 1637.3 (CI: 1383.0-1926.0), Intermediate SES = 3093.1 (CI: 2790.0-3420.0), Poor SES = 3381.1 (CI: 
3103.0-3677.0), Very poor SES = 4825.2 (CI: 4542-5122). X2 trend significant, p<0.001. Significant clusters detected for 
both pneumonia (RR: 1.78, p=0.001) and pneumonia hospitalisations (RR: 1.69, p=0.001).  
Non-random distribution (clustering) of pneumonia 
cases occurring in crowded areas with low 
socioeconomic conditions. Pneumonia 80% higher in 
regions with deprived socioeconomic conditions.  
G Identified four variables associated with increased Invasive Pneumococcal Disease: Density (increase of 100,000/mile2) 
RR: 1.10, Percentage black (10% increase) RR: 1.07, Percentage <5 years (10% increase) RR: 3.49, Percentage >65 (10% 
increase) RR: 1.19. High average income and neighbourhood population below poverty line also significantly inversely 
associated with IPD incidence (data not shown).  
Significant clusters of IPD identified, based on 
neighbourhood characteristics, namely density, ethnicity 
and age. SES an important factor in incidence rates.  
H  Detected significant clusters both pre- and post-earthquake. The pre-earthquake cluster (RR: 3.31, p=0.018) shifted 
southeast and had a higher relative risk in the post-earthquake period (RR: 4.13, p=0.021). A significant cluster was 
also found with regards to spatio-temporal analyses, with cases occurring from July 2010-November 2011 (RR: 3.01, 
p=0.022). Substantial overlap between clusters and areas of severe liquefaction and ejecta dust.  
Liquefaction does seem to be a factor in clustering of 
pneumococcal pneumonia, which is still very much 
influenced by pre-existing deprivation levels across all 
affected regions.  
I Significant six-fold variation between districts with regards to risk of pneumonia (RR: 0.44 – 2.92). Variables identified 
through multivariate models included material deprivation, distance to health centre, local domain health score, and 
number of children requiring assistance from local authority. Major clusters were identified in the southeast, in large 
urban centres, while the lowest risks were rural regions in the northwest.  
 
Significant spatial variation in pneumonia 
hospitalisations, which can be explained by levels of 
material deprivation, childhood illness and disability.  
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2.12.4 Discussion of review 
 As GIS analysis is an emerging field, studies on pneumonia or IPD distribution rates 
are by no means complete, nor do they currently offer a whole picture of why cases occur 
where they do. Each of the studies here focuses on several factors, none of which are 
common across all studies, and none of which fully explain any relationship between 
location and disease rates. Any inferences drawn from this review must also consider the 
complexity of disease spread and the necessity of a holistic approach to ensure that no 
detail is overlooked.   
 Socioeconomic status was the most common finding, touched on by 6 out of 9 
studies. B and F found a significant trend with pneumonia rates changing at an inversely 
proportional rate to the income of the region (p<0.001). Both studies used regional median 
household income to account for this, which provides area-level aggregation for individual 
level cases, which prevents conclusions from being made of the individuals, but does allow 
for regional conclusions. Feemster et al. did not show a trend line comparison, but did note 
a substantial association between high average income/neighbourhood population below 
poverty line, and IPD rates, while Pearson et al. showed a strong association between IPD 
rates and deprivation indexes, both before and after the earthquakes.  
Accessing health care services was another important finding, with A, B, F and I all 
reporting increasing cases in areas with either few healthcare resources, or else barriers to 
accessing them, namely distance. In addition to this, Blain et al. discuss the close 
relationship between socioeconomic status and accessing healthcare, with the cost of 
accessing health services acting as a barrier itself. Interestingly, Ali et al. showed that the 
type of healthcare was not necessarily important, with patients receiving just as much 
benefit from an allopathic practitioner than they would a standard health centre.   
Two studies (C and G) included ethnicity as a factor, both of which showed that 
being a minority was heavily associated with pneumonia and IPD respectively. This finding is 
difficult to interpret however, due to the many confounders associated with ethnic 
minorities, including SES and access to healthcare. In particular in study C, the Aboriginal 
people of Canada tend to live on isolated reservations, which have much higher rates of 
disease, alcoholism, and fewer medical services than the average town [96], which in turn 
will affect the clustering statistics of the overall area.  
Population density appeared as a significant factor in 5 studies, showing that rates of 
disease were related to the spatial distribution of people (high density/cities vs low 
density/rural areas), however with conflicting results. Studies C and D found the highest 
rates to be in rural regions, while G, H, and I all showed higher rates in populated urban 
areas. This difference could lie in the scale of analysis, as studies G and H were both 
restricted to the greater metropolitan area of cities, while I was a single varied region across 
habitable area. Studies C and D were held in the province of Ontario, which despite being 
the most populated province in Canada, the population is skewed heavily towards the 
south, with large tracts of land in the northern region with few to no inhabitants, which 
could affect the disparities shown between study results.  
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2.12.5 Summary of studies 
 Despite some similarities between risk factors across most studies, a lack of 
consistent disease identification, different study methods, geospatial analysis and primary 
outcomes make it very difficult to make many reliable conclusions from this review. 
Reasonable conclusions can be made about pneumonia and IPD clustering in general, as all 
studies showed at least a moderate amount of clustering, either by region or within cities. 
Risk factors are shown to be associated with high rates of disease, but it is unclear exactly 
how big the association is, and how it interacts with other risk factors. In particular, SES 
shows a particularly strong inverse trend with rates of pneumonia or IPD, even if some 
studies left it out of their analysis. Accessing healthcare is another area that was particularly 
important in these studies, where hospitalisation rates were frequently used to recruit 
cases. With the burgeoning emergence of GIS software usage in affairs of public health and 
infectious disease management, it is very surprising that it has not been used more to deal 
with pneumonia and IPD. This gap in knowledge affects a large area of research with a real 
need for spatial data analysis, and more work will need to be done before definitive 
conclusions can be drawn.  
 
2.12.6 Funding 
This literature review was conducted independently, without any contribution from 
any project funders, nor was any input given by any stakeholders involved. The University of 
Otago’s library, database access, and staff were used to access relevant texts, as well as 
plan, and execute the systematic review process. As the author, I have no conflicts of 
interest to declare.  
25 
 
Chapter 3 – Methods 
 
This chapter describes the methods used in this thesis, as well as the BHDSS and PSP 
programs. Section 1 describes the study aims and research questions. Section 2 provides 
background information on the study area, as well as the BHDSS and how it operates. 
Section 3 and 4 list the methods on how cases were recruited, and what inclusion criteria 
were required. Section 5 covers the data entry, manipulation and basic analysis, while 
Section 6 goes into more depth on each specific type of analysis. The chapter finishes with 
the ethical approval in section 7.  
 
3.1 Study Design 
3.1.1 Research Questions 
This project was nested in a larger pneumococcal surveillance project and aimed to 
identify geospatial differences between IPD and RCP after the introduction of a 
pneumococcal conjugate vaccine. The research questions were as follows: 
1) Do IPD and RCP map differently? If so, how do they differentiate spatially, and can 
this be explained by any measured variables? 
2) Are there differences in spatial distribution when comparing before-vaccine and 
after-vaccine time periods?  
3.1.2 My role in the study 
 I lived on site at the MRC Field Station for 7 months while the data collection was 
being finalised. During this time, I helped supervise and organise data extraction using the 
MRC databases, as well as cleaning and inspecting data for discrepancies.  I was then 
responsible for designing a system which linked multiple databases, to combine all 
information relevant to my project in one location. I was in charge of following up missing 
household locations, which involved coordinating, and when possible, participating with a 
team of field workers to scour the entire region for missing data points to be collected using 
handheld GPS transceivers. Simultaneously, with the help of my supervisor, I learned how to 
use GIS programs, which I then used to provide up to date maps of the region and various 
illnesses for other projects occurring at the field station. Upon returning to New Zealand, my 
role continued to involve data cleaning, in addition to sorting datasets for analysis, 
conducting analyses and using mapping software.  
 
3.2 Description of site 
This was based in the Upper River Region of Gambia, the easternmost region in the 
country.  Cases were identified from the Basse Health and Demographic Surveillance 
System. This system was set up in partnership between the Gambian Government and the 
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Medical Research Council, to monitor the impact that PCV-7 (and later PCV-13) would have 
on the population. The BHDSS comprises the southern part of the Upper River Region, 
consisting of the area south of the Gambia River (see Figure 3). This area has only one major 
health centre (Basse Health Centre), and five peripheral clinics providing inpatient and 
outpatient care, as well as referrals to the BHC. The Upper River Region is the furthest 
region inland from the capital city, and remains a rural province, comprising 225 small to 
medium sized villages. One notable exception is the Basse Santa Su Township itself, which 
serves as a capital and focal point for the entire Upper River Region, as well as being home 
to the MRC Field Station where this project was based. The BHDSS area is broken up into 20 
administrative regions of roughly equal population sizes. The surveillance area has a 
growing population, estimated to be 178,571 in December 2014, which is monitored by a 
team of clinicians, nurses, an epidemiologist and a radiographer, in addition to 
administrative staff. A dedicated surveillance staff member is located at each health facility 
within the BHDSS catchment. While the Pneumococcal Surveillance Project (PSP) is one of 
the main users of the BHDSS, there are several other projects that also make use of the 
demographic information.  
 
Figure 3: Map of Gambia, showing the Upper Rover Region relative to the rest of the 
country. Basse lies at the centre of the BHDSS area on the main road.  
The demographic surveillance system contains records of all births, deaths, 
immigration, emigration, pregnancies, and marriages, in addition to the vaccination status 
of any children. An incomplete list of ethnicity, educational status and household income is 
in progress. The surveillance system began its pilot implementation in July 2007, with an 
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official start occurring on the 12th of May 2008. Inclusion in the BHDSS requires a person to 
be born in the region, or else inhabit the region for two consecutive data collection rounds. 
Residents who are absent from the BHDSS region for two consecutive rounds are considered 
to have exited the region. Each resident was assigned a unique 14 digit ID number based on 
their location. The first five digits represented the village, while the next four digits 
identified the compound. The next two digits were used to determine which household 
within the compound the resident belonged to, while the final three digits were unique to 
the resident themselves. Village, compound and household digits were all determined 
according to imaginary blocks, set up in a grid-like pattern when commencing the 
surveillance system, while the last three digit resident identifier was collected during the 
rounds according to seniority in the household, with new additions added subsequently.   
Demographic information is collected through trained field workers who update the 
data for each household every four months (1 round) through site visits to each compound 
(See Figure 4 below). GPS coordinates are also taken for every household using handheld 
GPS receivers (Garmin GPSMAP 78), which are stored in a database and updated 
periodically. Any presentation to a regional health clinic will allow the case to be matched 
with the demographic information in the system, allowing routine surveillance data to 
supplement the clinical information. Cases that present to health facilities with pneumonia 
or pneumococcal disease are treated the same regardless of their DSS status, with the only 
exception being how the data is reported. All case data is recorded on Case Report Forms 
(CRFs), which are sent back to the Basse Field Station for data entry. CRF 1, 2, and 3 provide 
demographic and identifying information, as well as basic screening. CRF 4 and 5 are 
assessments of the patient, while CRF 6 lists the clinical outcomes, with 6.1 listing any 
transfers. CRF 7 is dedicated to the laboratory tests and results, with CRF 8 and 9 are for 
bacterial/isolate typing as well as sample storage. CRF 10 is an X-ray request and review 
form and CRF 11 is the radiology report from the x-ray. Depending on the case specifics, 
each case will have the relevant CRFs completed and inputted into the database (See 
Appendix 1).  
 
3.3 Case Recruitment 
All cases were identified from the BHDSS clinics from May 2008 until December 
2014. Children presenting to a health clinic with suspected pneumonia or IPD were 
evaluated by dedicated surveillance nurses who referred any patients who meet the 
inclusion criteria to clinicians who assess and confirm the diagnosis, as well as report the 
data. Diagnostic investigations were conducted, including chest x-ray, blood culture, rapid 
malaria tests, haemoglobin concentration, and lumbar puncture where appropriate. Figure 
4 below shows the process of recruiting a case from the initial presentation at a health 





Figure 4. Flowchart of PSP recruitment schematic on the left (red) and BHDSS methods on 
the right (blue).  
 
3.4 Case Criteria 
Identification of cases was initially reported through local surveillance nurses, and so 
a set of referral criteria was developed to ensure consistent and reliable reporting. Separate 
guidelines were available for children aged 2-59 months, and those 60 months and older. 
Suspected cases were then defined by the referring clinicians based on the following 
criteria, using sound clinical judgement. Once the diagnosis has been made by the clinician, 
the appropriate investigations are ordered, regardless of the inclusion/exclusion status of 
the case. Case criteria for surveillance nurses are listed below in Table 6, while clinician’s 
criteria for suspected pneumonia, meningitis and septicaemia are listed in Tables 7, 8, and 9 
respectively. Weight was one of the standard admittance procedure and any child weighing 





Table 6. Screening criteria for surveillance nurses.  
Screening Criteria for children presenting in the BHDSS as grounds for referral to a 
clinician 
Children aged 2-59 months Children aged 60 months and older 
 - History of cough or difficulty breathing, 
AND a raised respiratory rate for age (+50 
per minute if 1 year or less, and +40 per 
minute if older than one year) 
 - History of cough or difficulty breathing 
 - Axillary temperature less than 36C or 
greater than 38C in a patient 
 - Axillary temperature less than 36C or 
greater than 38C in a patient 
 - A history of convulsion  - A history of cough and pleuritic chest pain 
 - Impaired consciousness  - A history of cough and 
supraclavicular/sternal recession or nasal 
flaring 
 - Bulging fontanelle  - A history of productive cough and fever 
 - Stiff neck  - A history of rigors 
 - Prostration  - A history of seizures 
 - Lower chest wall indrawing, nasal flaring, 
or grunting 
 - Impaired consciousness 
 - Oxygen saturation less than 92%  - Altered mental state 
 - Weight below 3 z-score for age  - Stiff neck 
 - Local musculoskeletal swelling or 
tenderness 
 - Photophobia 
 - Suspected meningitis  - Local musculoskeletal swelling or 
tenderness 
 - Suspected meningitis 
 
 
Table 7. Criteria for clinicians for suspected pneumonia. 
Children aged 2-59 months Children aged 60 months and older 
- History of cough, or difficulty breathing 
plus at least one of the following: 
- If any two or more of the following 
symptoms are present: 
- Raised respiratory rate for age (+50 per 
minute if 1 year or less, and +40 per minute 
if older than 1 year) 
- Cough 
- Lower chest wall indrawing, nasal flaring, 
or grunting 
- Haemoptysis 
- Oxygen saturation of less than 92% - Pleuritic chest pain 
- Focal chest signs (dull percussion note, 
coarse crackles, bronchial breathing) 
- Breathlessness 





Table 8. Criteria for clinicians for suspected meningitis. 
Children aged 2-59 months Children aged 60 months and older 
- Patient is clinically unwell and any of the 
following are present: 
- Patient is clinically unwell and any two or 
more of the following are present: 
- Neck stiffness - Axillary temperature >38C 
- Impaired consciousness - Meningism (neck stiffness and/or 
photophobia) 
- Prostration - Altered mental state 
- History of convulsion  
  
 
Table 9. Criteria for clinicians for suspected septicaemia.  
Children aged 2-59 months Children aged 60 months and older 
- If any of the following are present: - If any of the following are present: 
- Clinician diagnosis of focal sepsis - Clinician diagnosis of focal sepsis 
- Axillary temperature is <36C or >38C 
with no obvious cause of fever 
- Axillary temperature is <36C or >38C 
with no obvious cause of fever 
- The clinical impression of the patient is of 
severe malnutrition 




3.5 Data Entry 
3.5.1 Data entry and identification 
All data were checked, before being double entered into a secure Microsoft Access 
database by data entry technicians. CRFs are stored in locked cupboards after their initial 
use for safety and to maintain a paper record. Case’s data were extracted into Microsoft 
Excel spreadsheets, where they were linked with supplementary data (education status, 
income, GPS coordinate data, etc.) based on BHDSS ID numbers. Cases of IPD were 
identified by extracting any cases where Streptococcus pneumoniae was recorded as the 
primary bacterial isolate from a sterile site (blood cultures, CSF, etc.). Radiologic pneumonia 
cases were identified by cross-referencing the results of the chest radiograph readings 
against a list of recorded suspected pneumonia cases. X-rays were read by two blinded 
readers based on WHO criteria for radiologic pneumonia. If there was a disagreement over a 
particular case, a third reader was brought in to break the tie.  
3.5.2 Data cleaning and exclusions 
Once extracted into Excel, data were sorted to identify exclusion criteria. Most 
notably, this was based on incomplete data (without BHDSS ID numbers, incomplete ID 
numbers, unrealistic dates, and those with untraceable records). Cases with 11 digit BHDSS 
ID numbers were included for geospatial analysis, as they still permitted identification of the 
household and its coordinates. 50 cases were identified as having both IPD and RCP, which 
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were excluded from the RCP files but included in the IPD files. Non-residents of the BHDSS 
area, or those who had left the area were excluded, as well as any compounds who refused 
to participate in the study. In addition to this, any cases where the patient was below 2 
months of age was excluded as the surveillance system is not set up to monitor infants this 
young.  
Several cases had multiple tests ordered for a single illness (e.g. a bacterial blood 
culture as well as a lung aspirate), in which case the number of each test was noted, and 
then excluded so that each case was only represented one time. Likewise, some cases 
returned to the health centres for additional tests, sometimes in the space of a few days. To 
avoid repeated reporting of the same case, a period of one month had to occur before a 
new test would be counted as a separate incident. Data were then visually inspected to 
ensure congruity between data per case (e.g. birthdates matching with sampling dates and 





Figure 5. Flowchart of data cleaning process with exclusions for IPD on the left (yellow) and 
RCP on the right (green). Note that the 50 cases with both IPD and RCP were counted as IPD.  
 
3.5.3 Data sorting for analysis 
Cases were then split into different categories for analysis. Across the entire time 
period, the data were divided into the following categories: All ages, Under 14 years, and 
Under 5 years, the last of which was further divided into 2-23 months and 24-59 months. 
These divisions were chosen to answer the first research question, namely, if any of above 
groups differed between the mapping of IPD and RCP across the entire study period. For the 
first three categories, IPD was split into two groups based on the serotype that was isolated 
from the laboratory results. Serotypes 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A 
were classified as Vaccine Type, as they are the serotypes that the PCV-13 protects against, 
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while all other types were classified as Non-Vaccine Type. Small sample sizes prevented 
vaccine type from being assessed in the 2-23 and 24-59 month groups.  
A specific, pre-vaccine, time period was included in the first question analysis, which 
had the same age categories, restricted to the first 24 months of the study (May 2008-May 
2010). Again due to small sample sizes, we were not able to analyse the vaccine types of the 
2-23 and 24-59 month groups.  
In order to answer the second research question, we focused on a particular set of 
patients, namely those between the ages of 2-59 months, within two specific time periods. 
A “Before Vaccine” time was chosen to be the beginning of the study, plus two years, while 
the “After Vaccine” time period was based on the latest data collection round in the BHDSS, 
minus two years. This allowed us to compare distributions from May 2008-2010 to 
December 2012-2014. These dates were selected based on findings of significant reductions 
in IPD and RCP cases in these groups, showing that the vaccine was having a measurable 
effect in the population [97].   
 
3.6 Software Programs 
3.6.1 GIS 
 Most maps in this thesis were made using ArcGIS versions 10.0 and 10.3 (ESRI, 
Redlands, California). Coordinates of interest were copied into comma separated value files, 
which were able to be directly added to the GIS. The output maps were produced using a 
geographic coordinate system, World Geodetic System 1984. Polygon shapes of the regions 
in the URR had been mapped in a previous study, and were therefore able to be easily 
incorporated into the GIS, with minimal changes other than switching the coordinate system 
from projected to geographic. Health facilities had all been geocoded and added into the 
GIS, as well as additional data such as main and secondary road systems. Annotated 
polygons of each settlement were included to make for easier identification of villages while 
working in the GIS. An example of an output map can be seen below in Figure 6, which 
shows the 20 regions in the BHDSS region. Population data were able to be loaded in to the 
GIS so that regional incidence rates could be calculated and mapped. Very little statistical 
analysis was conducted using the ArcGIS analysis tools, instead opting for more specific 




Figure 6. Example of ArcGIS output, showing the 20 regions in the BHDSS. 
 
3.6.2 SaTScan 
 Statistical analysis of disease cases were performed with the freeware program 
SaTScan©. This program tests for statistically significant clusters of cases and identifies 
hotspots. Data were aggregated to regions, and sorted by years. Purely spatial models used 
case, coordinate and population data, based on a Poisson distribution. This assumes a 
proportionate number of cases occur according to the underlying population at risk [98]. 
SaTScan creates a virtual circular window which moves around the area, increasing and 
decreasing in size to accommodate the population at risk captured within the circle. A 
maximum of 50% of the total population was used, in order to identify high risk clusters, 
depending on the overlap of the windows [99]. At each location, and with each circle size, 
the number of observed and expected cases are noted. Identified clusters are then tested 
for significance using likelihood ratios from Monte Carlo simulations of a null distribution. 
Monte Carlo simulations were run for 999 replications. In order to properly identify the 
geographic perimeters of the regions, the centroid of each region was calculated using 
ArcGIS, which was included in each analysis. Each output file included details on hierarchical 
clusters, location information, risk estimates, and simulated log likelihood ratios. All clusters 
are presented in tables in the Results section, however only significant clusters were 








 In addition to standard spatial scan statistics, we used an innovative adaptive kernel 
smoothing model, which allows the comparison between two sets of diseases. Basic kernel 
smoothing is often used when comparing differences between case and control densities, 
and although it offers many advantages such as ease-of-use and popularity, it cannot 
properly adjust for geographical features that affect human population density (towns, 
mountains, rivers, etc.). Adaptive kernel smoothing is a novel method that adaptively 
applies more smoothing in areas of low density, to avoid isolated outliers disproportionately 
affecting results, and less smoothing in areas of high density, allowing finer details to 
emerge unhindered [100]. These results can be visualised in surface plots based on kernel 
density ratios, with the formula “R=log10(f/g)”, where “R” is the relative risk, and “f” and “g” 
are the two disease sets being compared, which are replaced by codes for ease of analysis. 
Invasive Pneumococcal Disease was given the code B, Radiologically confirmed pneumonia 
was given the code A, Vaccine-type serotypes were coded C, and Non-vaccine-type 
serotypes were coded D. All case location data were compared to control location data 
using the underlying population to provide an “at-risk distribution.” This allows for a direct 
comparison of the spatial point patterns, resulting in a relative risk statistic being produced 
[101]. All adaptive kernel smoothing calculations were created using sparr, a spatial 
modelling approach for R, a statistical and graphical programming language [101].  
 
3.7 Ethics 
This study operates under the ethics approval granted to the BHDSS program by the 
Joint National government of the Gambia/MRC (UK) ethics committee of Gambia. 
Implementation of the surveillance system was done with the support of local, regional and 
national bodies, as well as support from the community. As the screening process is nothing 
more than enhanced routine care, informed consent was only required for invasive 
procedures, the storage of biological samples, and the storage of identifiable records. All 
data and paper forms are stored securely at the MRC compound, with multiple data checks 
to ensure accurate input. All biological samples are stored in secure freezer rooms for 
possible future analysis.  
 
3.8 Statistics 
 Non-spatial statistical analyses were completed using STATA software, version 13 
[102]. 2-sample T tests were used for comparing risk factors of IPD and RCP, specifically with 
regards to age categories. Alpha levels of 0.05 were used to assess significance. One-way 
Analysis of variance (ANOVA) were used to analyse IPD, RCP, or Both groups when 




Chapter 4 – Results 
 
This chapter covers the results obtained from this project. Section 1 provides 
demographic and serotype information, and addition to baseline case maps. Section 2 
presents results related to the first research question using both cluster hotspot analyses 
and kernel density smoothing risk surfaces. Section 3 focuses on the before and after 
vaccine time periods, using similar analysis strategies as Section 2.  
 
4.1 Case demographics 
4.1.1 Comparing IPD to RCP 
 Over the course of the study, a total of 2089 cases of disease met the criteria for 
inclusion in this analysis, split into 320 IPD cases and 1769 RCP cases. 50 of these cases met 
both criteria, but were treated as IPD cases in the analysis. Males accounted for just over 
half of the cases for both endpoints. The average age was approximately 6 years and 4 
months for both diseases, although IPD had a higher median age. Only 10% of cases were 
aged 15 and above, while almost 75% of cases were under the age of 5.  Proportionally, 
both diseases had very similar divisions by age categories, and while 7% of cases were listed 
as malnourished, approximately a quarter had missing data. The most common case 
ethnicity was Serehule, followed by Mandinka and Fula. Both groups reported reasonably 
similar proportions had received their first PCV vaccine, although there was a drop off when 
following up with the second and third dose, so that 10% fewer of the original group had 
received all three doses. More detail is provided below in Table 10. Significance was tested 
using a two sample T-test with unequal variances. Of the original case records, 91 records 
were excluded from the starting 411 IPD records (See Section 3.5.2), while 15,462 records 
were excluded from the starting 17,231 records of RCP. The majority of these were excluded 
on the basis of failing to qualify for X-ray confirmed pneumonia, which only confirmed 











Table 10. Basic demographic information of cases. † represents significance (p<0.05) while ‡ 
represents extreme significance (p<0.001). Numbers may not equal 100% due to rounding. 
 IPD (320) RCP (1769) 
Sex 193 Male (60.3%) 946 male (53.5%) 
   
Average age (months) 76.41 (60.13 – 92.68) 76.81 (69.22 – 84.41) 
Median (months) 24 19 
   
Age groups   
All ages 320 (100%) 1769 (100%) 
Under 14 286 (89.4%) 1572 (88.9%) 
Under 5 248 (77.5%) 1396 (78.9%) 
24-59 months‡ 95 (29.7%) 1006 (56.9%) 
2-23 months‡ 153 (47.8%) 390 (22.1%) 
   
Malnourished   
Yes 23 (7.2%) 129 (7.3%) 
No 221 (69.1%) 1261 (71.3%) 
No data 76 (23.8%) 379 (21.4%) 
   
Ethnicity   
Fula 81 (25.3%) 464 (26.2%) 
Mandinka 104 (32.5%) 481 (27.2%) 
Serahule 116 (36.3%) 724 (40.9%) 
Wolof 1 (0.3%)  16 (0.9%) 
Other 5 (1.6%) 33 (1.9%) 
Jola 0 1 (0.1%) 
No data 13 (4.1%) 50 (2.8%) 
   
PCV received (1st dose)   
Yes† 125 (39.1%) 801 (45.3%) 
No 113 (35.3%) 555 (31.4%) 
No data 82 (25.6%) 413 (23.3%) 
   
Received all 3 doses PCV 93 (29.1%) 583 (33.0%) 
 
The Under 5 age group subcategories show a significant difference, with the younger 
group (2-23 months) in the IPD column containing almost two thirds of the eligible cases, 
while the RCP column is closer to one fifth. The older subcategory (24-59 months) appears 
to be weighted more heavily towards RCP, with 1006 of the eligible 1396 cases occurring at 
this age.  
A large number of cases appeared on both disease lists, having been diagnosed with 
IPD and RCP. These cases (n = 50), were included as IPD cases, however it was important to 
examine these cases themselves to see if were any significant differences. Single factor 
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ANOVAs were used to analyse the groups. The comparison table can be seen below as Table 
11, and is identical to Table 10, but with IPD split into solely IPD and IPD+RCP.  
 
Table 11. Comparisons of cases with IPD, RPD, or Both. † represents significance (p<0.05) 
while ‡ represents extreme significance (p<0.001). Numbers may not equal 100% due to 
rounding. 
 IPD (n = 270) Both (n = 50) RCP (n = 1769) 
Sex (male)‡ 153 (57%) 40 (80%) 946 (54%) 
    






Median (months)‡ 24 66 19 
    
Age groups    
All ages 270 (100%) 50 (100%) 1769 (100%) 
Under 14‡ 259 (95.9%) 26 (52.0%) 1572 (88.9%) 
Under 5† 224 (83.0%) 24 (48.0%) 1396 (78.9%) 
24-59 months‡ 90 (33.3%) 5 (10.0%) 1006 (56.9%) 
2-23 months† 134 (49.6%) 19 (38.0%) 390 (22.1%) 
    
Ethnicity    
Fula 66 (24.4%) 15 (30.0%) 464 (26.2%) 
Mandinka 87 (32.2%) 17 (34.0%) 481 (27.2%) 
Serahule 103 (38.1%) 13 (26.0%) 724 (40.9%) 
Wolof 0 1 (2.0%)  16 (0.9%) 
Other 3 (1.1%) 2 (4.0%) 33 (1.9%) 
Jola 0 0 1 (0.1%) 
No data 11 (4.1%) 2 (4.0%) 50 (2.8%) 
    
PCV received (1st dose)    
Yes‡ 113 (41.9%) 12 (24.0%) 801 (45.3%) 
No‡ 87 (32.2%) 26 (52.0%) 555 (31.4%) 
No data 70 (25.9%) 12 (24.0%) 413 (23.3%) 
    
Received all 3 doses 
PCV 
82 (30.4%) 11 (22.0%) 583 (33.0%) 
 
4.1.2 Vaccine serotypes 
All IPD cases had laboratory confirmed serotyping performed on them. Serotypes are 
divided into Vaccine Type (VT) and Non-Vaccine Type (NVT) depending on their inclusion, or 
not, in the PCV-13. VT serotypes were more common, with 222 samples falling under this 
group, while NVT had 98 samples. A comparison table was made by examining the 
demographic characteristics of those cases with VT serotypes, and those without (NVT). The 
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results can be seen below in Table 12. VT and NVT differ significantly with regards to age, 
with VT cases being almost 3 times older, while almost 75% of NVT cases were in the 2-23 
month category. VT and NVT also were significantly different in terms of cases of no 
malnutrition and those who did not report anything, although those with malnutrition were 
not statistically different. There was no significance between any ethnic groups. Vaccination 
status shows quite a marked change, with over twice the percentage of people in the NVT 
group receiving the first PCV dose (64.3%), whereas the VT group only had 27.9%. Again, 
over twice as many NVT cases had received the full 3 dose schedule as VT (44.9% to 22.1%) 
In addition to case demographics, the serotypes themselves were examined for 
patterns. The most common vaccine type by far was type 1, which had twice as many as the 
second most common one, type 5. Non-vaccine types were extremely varied, with most only 
showing up a few times throughout the samples. The exception was type 12F, which 
accounted for 31% of the NVT burden. This is a fivefold difference from the next highest 
serotype count, and none of the other serotypes were found in more than 6 samples. 
Frequency counts can be seen below in Appendix 2 for VT, and in Appendix 3 for NVT. Visual 
representations are provided below in Figure 7 and Figure 8, showing a pie chart of Vaccine 
Types, and a bar graph of Non-Vaccine Type frequency. Note that although PCV-13 does 
include 13 serotypes, no cases of 7F or 18C were found during the study period, and that 
6A/B are listed together due to cross sensitivity.  
   
  
Table 12. Basic demographic information of serotype specific cases. † represents 
significance (p<0.05) while ‡ represents extreme significance (p<0.001). Numbers may not 
equal 100% due to rounding.  
 VT (222) NVT (98) 
Sex 134 Male (60.4%) 59 Male (60.2%) 
   
Average age (months)‡ 87.61 (67.50 – 107.72) 51.02 (23.82 – 78.22) 
Median (months)‡ 32 10 
   
Age groups   
All ages 222 (100%) 98 (100%) 
Under 14 194 (87.4%) 91 (92.9%) 
Under 5‡ 159 (71.6%)  89 (90.8%) 
24-59 months† 78 (35.1%) 17 (17.4%) 
2-23 months‡ 81 (36.5%)  72 (73.5%) 
   
Malnourished   
Yes 13 (5.9%) 10 (10.2%) 
No† 144 (64.9%) 77 (78.6%) 
No data‡ 65 (29.3%) 11 (11.2%) 
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Ethnicity   
Fula 58 (26.1%) 23 (23.5%) 
Mandinka 70 (31.5%) 34 (34.7%) 
Serahule 79 (35.6%) 37 (37.8%) 
Wolof 1 (0.5%) 0  
Other 5 (2.3%) 0 
No data 9 (4.1%)  4 (4.1%) 
   
PCV received (1st dose)   
Yes‡ 62 (27.9%) 63 (64.3%) 
No‡ 94 (42.3%) 19 (19.4%) 
No data† 66 (29.7%) 16 (16.3%) 
   









Figure 8. Bar graph showing the counts of Non-Vaccine Type serotypes occurring during the 
study.  
 
4.1.3 Incidence rates 
 Incidence rates were calculated for each of the 20 regions, for each year of the 
project. Population data, which was collected three times a year, was averaged to produce a 
yearly mean with which to calculate the rates. Rates were first calculated using all IPD and 
RCP cases in the Under 14 years group (Tables 13 and 14, respectively), and then again using 
only data from the Under 5 years group (Tables 15 and 16 for IPD and RCP respectively). 
Incidence rates varied widely among the IPD group, where due to small sample sizes, there 
were often blank spaces where no disease had occurred that year. Some regions varied 
drastically even within themselves, with the Bakadaji region jumping from a rate of 0 
cases/100,000 in the Under 14 group in 2009, only to have a rate of 246 cases/100,000 a 
mere two years later. IPD rates ranged from 0 to 246 in the Under 14 group, and 0 to 513 in 
the Under 5 group. Overall trends for both age groups show a rising rate peaking in 2010, 
then falling until 2014 where the rate begins to rise slightly. RCP rates were much higher, 
and ranged from 0 to 940 in the Under 14 group, and from 0 to 2534 in the Under 5 group. 
Due to the surveillance system’s starting point in May 2008, the first year only collected 
data for 8 months, which has most likely resulted in an underestimation of the true 
incidence rates. All other years have recorded a full 12 months’ worth of data collection. In 
order to better visualise the data, overall incidence rates were graphed for both Under 14 
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and Under 5 groups. Results can be seen in Figures 9 and 10, which show the slope of the 
trend (indicating its positive or negative angle), and the R2 value, which indicates how 





Table 13. IPD incidence rates in the Under 14 group across the whole time period. Values are in cases per 100,000 with 95% confidence 
intervals. 
Regions 2008 2009 2010 2011 2012 2013 2014 
Allunhari 123 (46-328) 115 (32-416) 80 (26-248) 52 (13-207) 0 (0-0) 0 (0-0) 49 (12-195) 
Bakadaji 81 (26-251) 0 (0-0) 101 (38-270) 246 (132-457) 0 (0-0) 0 (0-0) 44 (11-175) 
Banico Kekoro 0 (0-0) 174 (87-348) 126 (57-280) 80 (30-213) 38 (10-154) 0 (0-0) 92 (38-221) 
Basse 0 (0-0) 95 (40-229) 71 (27-190) 34 (8-135) 32 (8-129) 64 (24-171) 33 (8-131) 
Dampha Kunda 61 (15-244) 58 (14-231) 197 (94-413) 136 (57-328) 131 (54-314) 77 (25-239) 51 (13-203) 
Demba Kunda Moribugu 29 (4-204) 28 (4-201) 54 (14-217) 0 (0-0) 51 (13-205) 51 (13-203) 50 (12-199) 
Diabugu Alpha 0 (0-0) 59 (15-236) 86 (28-265) 28 (4-200) 27 (4-193) 0 (0-0) 26 (4-185) 
Dingiri 24 (3-169) 47 (12-187) 22 (3-157) 85 (32-227) 101 (42-242) 58 (19-180) 38 (9-150) 
Fatoto 0 (0-0) 0 (0-0) 33 (5-233) 32 (5-227) 62 (16-249) 0 (0-0) 60 (15-240) 
Gambisara 84 (32-225) 79 (30-211) 113 (51-252) 93 (39-223) 36 (9-145) 53 (17-165) 18 (3-126) 
Garawol 0 (0-0) 28 (4-201) 78 (25-242) 49 (12-197) 142 (64-317) 0 (0-0) 46 (11-182) 
Julangel 0 (0-0) 0 (0-0) 25 (4-177) 48 (12-191) 45 (11-181) 22 (3-155) 21 (3-152) 
Kaba Kama 60 (15-239) 56 (14-225) 79 (26-246) 127 (53-305) 49 (12-197) 48 (12-191) 47 (12-188) 
Keneba 0 (0-0) 68 (17-271) 97 (31-300) 62 (15-246) 30 (4-216) 0 (0-0) 61 (15-243) 
Koina 0 (0-0) 74 (18-295) 70 (18-281) 34 (5-240) 0 (0-0) 0 (0-0) 86 (28-268) 
Kunlari 27 (4-191) 159 (71-353) 122 (51-294) 24 (3-167) 45 (11-180) 44 (11-175) 22 (3-155) 
Mansajang 99 (14-703) 0 (0-0) 93 (13-662) 91 (13-645) 0 (0-0) 0 (0-0) 0 (0-0) 
Misira Ba Mariama 31 (4-217) 0 (0-0) 0 (0-0) 25 (4-178) 24 (3-170) 46 (12-185) 0 (0-0) 
Numuyel 87 (28-270) 82 (27-255) 157 (71-349) 98 (37-262) 115 (48-277) 45 (11-180) 67 (22-209) 
Sabi 67 (2-268) 95 (31-293) 31 (4-218) 0 (0-0) 57 (14-230) 0 (0-0) 55 (14-218) 





Table 14. RCP incidence rates in the Under 14 group across the whole time period. Values are in cases per 100,000 with 95% confidence intervals. 
Region 2008 2009 2010 2011 2012 2013 2014 
Allunhari 123 (46-328) 430 (260-713) 401 (242-664) 466 (294-739) 522 (341-800) 613 (415-907) 342 (203-576) 
Bakadaji 108 (41-287) 157 (70-348) 279 (154-502) 246 (132-457) 512 (338-777) 247 (137-445) 569 (388-835) 
Banico Kekoro 268 (152-471) 326 (197-541) 462 (304-701) 601 (421-859) 481 (325-711) 489 (333-718) 589 (417-832) 
Basse 160 (80-319) 153 (76-305) 321 (202-509) 236 (140-399) 386 (259-576) 240 (145-399) 441 (303-643) 
Dampha Kunda 244 (122-487) 550 (351-861) 338 (192-594) 600 (396-911) 940 (679-1301) 771 (540-1102) 608 (408-907) 
Demba Kunda Moribugu 57 (14-230) 170 (76-378) 245 (127-470) 262 (141-487) 384 (232-637) 355 (210-598) 398 (244-649) 
Diabugu Alpha 154 (64-369) 207 (99-433) 114 (43-304) 479 (298-769) 462 (288-743) 265 (143-492) 182 (87-382) 
Dingiri 167 (79-349) 469 (303-726) 199 (104-382) 447 (292-685) 485 (325-722) 290 (175-481) 207 (115-374) 
Fatoto 71 (18-284) 446 (259-768) 262 (131-524) 831 (567-1218) 591 (378-926) 767 (519-1134) 270 (141-519) 
Gambisara 190 (99-365) 376 (240-589) 302 (185-493) 540 (375-776) 728 (535-991) 552 (388-784) 532 (372-760) 
Garawol 159 (66-383) 593 (387-909) 287 (159-517) 492 (318-762) 546 (363-821) 388 (241-623) 457 (295-707) 
Julangel 27 (4-193) 0 (0-0) 25 (4-177) 143 (64-319) 113 (47-271) 44 (11-175) 64 (21-199) 
Kaba Kama 239 (120-478) 338 (192-595) 317 (180-558) 686 (471-1000) 741 (519-1058) 789 (562-1108) 518 (341-786) 
Keneba 491 (291-827) 237 (113-497) 420 (244-722) 524 (326-842) 456 (275-756) 609 (393-942) 668 (440-1013) 
Koina 40 (6-284) 665 (419-1053) 105 (34-326) 406 (231-715) 794 (537-1173) 509 (317-818) 374 (218-644) 
Kunlari 162 (73-359) 344 (200-591) 294 (167-517) 566 (380-843) 449 (290-696) 372 (232-598) 525 (352-782) 
Mansajang 198 (50-792) 288 (93-891) 187 (47-745) 273 (88-845) 795 (415-1524) 435 (181-1043) 175 (44-700) 
Misira Ba Mariama 31 (4-217) 311 (172-561) 234 (122-450) 226 (118-434) 287 (163-505) 277 (157-487) 358 (219-583) 
Numuyel 174 (78-387) 384 (228-648) 157 (71-349) 762 (537-1082) 670 (466-963) 496 (327-752) 697 (491-990) 
Sabi 134 (50-358) 379 (215-666) 154 (64-369) 329 (183-594) 402 (238-678) 249 (130-478) 246 (128-472) 







Table 15. IPD incidence rates in the Under 5 group across the whole time period. Values are in cases per 100,000 with 95% confidence intervals. 
Region 2008 2009 2010 2011 2012 2013 2014 
Allunhari 266 (86-825) 318 (120-847) 72 (10-510) 137 (34-549) 0 (0-0) 0 (0-0) 134 (34-534) 
Bakadaji 209 (67-647) 0 (0-0) 257 (97-683) 492 (246-981) 0 (0-0) 0 (0-0) 113 (28-452) 
Banico Kekoro 0 (0-0) 429 (215-857) 309 (139-688) 190 (72-506) 0 (0-0) 0 (0-0) 142 (46-439) 
Basse 0 (0-0) 238 (99-572) 136 (44-421) 85 (21-341) 0 (0-0) 41 (6-289) 86 (21-342) 
Dampha Kunda 165 (41-658) 75 (11-535) 513 (245-1075) 349 (146-838) 200 (65-620) 195 (63-603) 128 (32-511) 
Demba Kunda Moribugu 75 (11-530) 73 (10-516) 70 (10-493) 0 (0-0) 68 (10-479) 67 (10-477) 133 (33-531) 
Diabugu Alpha 0 (0-0) 147 (37-587) 144 (36-576) 71 (10-504) 68 (10-486) 0 (0-0) 66 (9-471) 
Dingiri 58 (8-415) 114 (29-456) 0 (0-0) 207 (78-551) 249 (104-598) 144 (46-446) 95 (24-379) 
Fatoto 0 (0-0) 0 (0-0) 86 (12-613) 82 (12-582) 0 (0-0) 0 (0-0) 151 (38-604) 
Gambisara 225 (84-598) 154 (50-477) 196 (74-522) 232 (97-558) 91 (23-364) 139 (45-429) 48 (7-340) 
Garawol 0 (0-0) 70 (10-498) 61 (9-431) 57 (8-401) 336 (151-746) 0 (0-0) 111 (28-443) 
Julangel 0 (0-0) 0 (0-0) 64 (9-455) 119 (30-475) 113 (28-453) 54 (8-385) 53 (8-379) 
Kaba Kama 150 (38-599) 140 (35-558) 199 (64-616) 324 (135-778) 128 (32-512) 126 (32-503) 126 (32-504) 
Keneba 0 (0-0) 82 (12-582) 157 (39-628) 73 (10-519) 75 (11-529) 0 (0-0) 164 (41-655) 
Koina 0 (0-0) 172 (43-686) 161 (40-643) 77 (11-544) 0 (0-0) 0 (0-0) 138 (35-552) 
Kunlari 0 (0-0) 295 (111-786) 321 (134-770) 0 (0-0) 114 (29-457) 110 (28-441) 0 (0-0) 
Mansajang 273 (39-1929) 0 (0-0) 277 (39-1961) 270 (38-1914) 0 (0-0) 0 (0-0) 0 (0-0) 
Misira Ba Mariama 79 (11-559) 0 (0-0) 0 (0-0) 61 (9-431) 59 (8-419) 116 (29-464) 0 (0-0) 
Numuyel 243 (79-753) 153 (38-611) 291 (109-773) 195 (63-603) 180 (58-558) 117 (29-466) 60 (8-424) 
Sabi 172 (43-686) 234 (76-724) 74 (11-527) 0 (0-0) 141 (35-562) 0 (0-0) 70 (10-496) 








Table 16. RCP incidence rates in the Under 5 group across the whole time period. Values are in cases per 100,000 with 95% confidence intervals. 
Region 2008 2009 2010 2011 2012 2013 2014 
Allunhari 266 (86-825) 1034 (602-1776) 935 (544-1607) 1236 (781-1957) 1478 (976-2237) 1412 (924-2159) 937 (556-1577) 
Bakadaji 278 (105-741) 464 (222-972) 385 (173-856) 860 (511-1449) 709 (403-1246) 497 (259-953) 1301 (867-1952) 
Banico Kekoro 554 (299-1029) 751 (446-1265) 928 (586-1470) 1331 (922-1924) 974 (636-1490) 1161 (786-1715) 1276 (877-1856) 
Basse 406 (203-810) 429 (224-824) 679 (410-1124) 512 (291-900) 1014 (686-1497) 611 (369-1012) 1026 (689-1528) 
Dampha Kunda 659 (330-1315) 1356 (857-2146) 880 (501-1546) 1537 (1016-2327) 2534 (1852-3470) 1686 (1152-2468) 1535 (1032-2282) 
Demba Kunda 
Moribugu 
150 (37-597) 364 (15-872) 417 (188-927) 592 (309-1136) 878 (511-1509) 740 (411-1333) 998 (603-1650) 
Diabugu Alpha 394 (164-944) 441 (198-979) 360 (150-864) 1135 (698-1848) 1027 (621-1700) 596 (311-1144) 398 (179-885) 
Dingiri 468 (234-934) 1027 (649-1627) 325 (146-722) 984 (629-1539) 1195 (803-1779) 576 (327-1012) 475 (256-881) 
Fatoto 188 (47-751) 883 (48-1636) 863 (466-1601) 1805 (1193-2731) 1344 (838-2155) 1622 (1061-2479) 454 (204-1008) 
Gambisara 506 (264-970) 873 (544-1402) 686 (408-1157) 976 (638-1494) 1687 (1226-2322) 1154 (782-1704) 1340 (928-1936) 
Garawol 342 (129-910) 1264 (799-2000) 546 (285-1048) 1018 (643-1612) 1175 (768-1797) 759 (450-1278) 888 (545-1446) 
Julangel 70 (10-499) 0 (0-0) 64 (9-455) 297 (124-713) 113 (28-453) 109 (27-434) 214 (80-569) 
Kaba Kama 600 (301-1198) 698 (376-1294) 663 (357-1229) 1362 (891-2083) 1793 (1242-2588) 1950 (1376-2763) 1260 (815-1948) 
Keneba 1121 (653-1924) 492 (222-1094) 629 (315-1254) 1024 (608-1725) 895 (510-1573) 1238 (761-2015) 1721 (1127-2630) 
Koina 289 (93-895) 1375 (845-2236) 242 (78-748) 844 (468-1519) 1624 (1073-2457) 1205 (751-1933) 691 (372-1281) 
Kunlari 453 (204-1007) 886 (505-1557) 578 (301-1109) 1320 (871-1999) 916 (562-1491) 883 (542-1438) 1173 (758-1813) 
Mansajang 545 (137-2171) 536 (135-2136) 555 (139-2207) 540 (136-2153) 1847 (887-3848) 1024 (386-2712) 534 (134-2130) 
Misira Ba 
Mariama 
158 (39-629) 742 (412-1336) 498 (250-994) 546 (285-1048) 591 (319-1096) 754 (439-1296) 927 (569-1510) 
Numuyel 487 (219-1081) 1148 (694-1898) 799 (444-1440) 1234 (789-1929) 1561 (1066-2285) 1283 (847-1943) 1671 (1158-2414) 
Sabi 343 (129-913) 780 (420-1445) 371 (155-890) 499 (239-1045) 985 (585-1659) 616 (321-1182) 489 (234-1024) 




Figure 9. Incidence rates of IPD over the study period. The red trend line represents the 
Under 14 group with a slope of -2.96x+65.86 (R2= 0.12), while the yellow represents Under 5 




Figure 10. Incidence rates of RCP over the study period. The blue trend line represents the 
Under 14 group with a slope of 43.96x+193.29 (R2= 0.58), while the green represents Under 




4.2 Mapping RCP and IPD 
 The primary goal of this thesis was to map both IPD and RCP cases throughout the 
study period to look for similarities or differences in the distribution of cases. Cases were 
first mapped showing all cases across all time periods (Figures 11 and 12 for IPD and RCP 
respectively). This shows the general distribution of all cases, which, if compared to Figure 
13 (a map of the settlements in the BHDSS), shows groupings of disease around the more 
populated settlements. While these preliminary maps do not account for time or 
background population, they allow for a rough interpretations of areas to focus.  
 
 
Figure 11. Distribution of IPD cases across entire study period. The inner lines denote the 




Figure 12. Distribution of RCP cases across entire study period. The inner lines denote the 
individual regions within the BHDSS.  
 
Figure 13. Settlement polygons in the BHDSS. The orange boundaries indicate the village 
limits, and offer a rough approximation of the populated areas.  
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4.2.1 SaTScan hotspot analysis 
 Using the SaTScan program, datasets were scanned for clusters of cases with higher 
observed rates than expected based on the background population, in addition to the spatial 
proximity of the cases. Output files have been condensed into Table 17 below for ease of 
access. All age group categories are listed down the left hand side, with the two different 
time periods (Whole time period and the 1st 24 months) for each of the four categories (IPD, 
RCP, VT, and NVT). Clusters are presented in hierarchical order from which they appear. The 
number of regions of each cluster is provided, in addition to the number of expected and 
observed cases, which provides a direct quotient as well as a relative risk statistic (RR). 
Significance is determined by evidence of Gini clustering (not pictured) and log likelihood 
ratios (not pictured), and produces p-values which have been included for ease of 
comparability. Clusters that have significant p-values are indicated in the cluster order 
column with a mark, and these are the clusters that are then mapped. Non-significant 
clusters are not mapped any further. Relative risks range from 1.11 to 3.35, although the 
majority of the significant clusters sit around 2.0. Most IPD age group cases are 
characterised by a single central cluster, containing a large number of regions. RCP cases 
have more secondary clusters for almost all age group categories than IPD, but tend to be 
smaller in terms of numbers of regions. The SaTScan model imposes restrictions on 
overlapping clusters, so the case data is not reused twice, creating a false inflated set of 
clusters [103]. Table 17 shows the geospatial distribution of clusters of diseases and their 
subsets.
 
Table 17. Spatial statistics of cluster analysis (Significance codes † p<0.05, ‡ p<0.001).  























All ages 1† 9 131.8 160 1.21 1.48 0.025 
Under 14 
years 
1† 9 130 159 1.22 1.50 0.017 
Under 5 years 1† 9 112.8 141 1.25 1.58 0.0089 
 2 2 30.2 40 1.32 1.39 0.744 
2-23 months 1 8 60.2 79 1.31 1.64 0.071 
24 to 59 
months 
1† 3 17.4 31 1.78 2.10 0.033 
 2 2 13 17 1.31 1.36 0.992 
 3 5 23 24 1.18 1.24 0.996 














All ages 1† 8 46 64 1.39 1.86 0.027 
 2 1 6.3 9 1.43 1.46 0.999 
Under 14 
years 
1† 9 46 62 1.35 1.92 0.045 
 2 1 5.3 8 1.5 1.54 0.999 
Under 5 years 1† 9 40.5 56 1.38 2.07 0.026 
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2-23 months 1 6 10.4 16 1.53 2.03 0.56 
















All ages 1‡ 2 171.7 250 1.46 1.53 0.00000029 
 2† 4 300.5 367 1.22 1.28 0.002 
 3† 2 178.3 225 1.26 1.30 0.02 
 4 1 121.3 155 1.28 1.30 0.069 
Under 14 
years 
1‡ 2 150.9 217 1.44 1.51 0.0000007 
 2‡ 4 264 338 1.28 1.36 0.00009 
 3 2 156.6 195 1.24 1.28 0.068 
 4 1 106.5 137 1.29 1.31 0.110 
Under 5 years 1‡ 2 133.8 195 1.46 1.53 0.000014 
 2‡ 4 234 301 1.29 1.37 0.00025 
 3 2 138.9 171 1.23 1.26 0.145 
 4 1 94.5 117 1.24 1.26 0.346 
2-23 months 1† 1 15.7 30 1.91 1.99 0.038 
 2 1 26.5 42 1.58 1.65 0.110 
 3 8 160 183 1.14 1.27 0.352 
 4 1 18.9 28 1.48 1.52 0.615 
 5 1 18.3 25 1.37 1.39 0.915 
24-59 months 1‡ 8 409.4 492 1.20 1.40 0.0000092 
 2‡ 2 96.2 147 1.53 1.62 0.000024 
 3‡ 4 168.4 223 1.32 1.42 0.00049 
 4 1 51.5 67 1.30 1.32 0.521 
 5 1 14 18 1.29 1.30 0.998 














All ages 1‡ 8 228.6 300 1.31 1.65 0.00000011 
 2‡ 2 57.8 94 1.63 1.75 0.00015 
 3‡ 2 56.7 92 1.62 1.74 0.0002 
 4 1 37.4 51 1.36 1.40 0.515 
 5 1 40.7 52 1.28 1.30 0.801 
Under 14 
years 
1‡ 6 144.4 199 1.38 1.64 0.0000044 
 2† 2 48 77 1.6 1.72 0.0014 
 3† 3 62 92 1.48 1.59 0.0039 
 4 1 33.9 46 1.36 1.40 0.571 
 5 4 108 119 1.1 1.13 0.993 
Under 5 years 1‡ 6 127.4 183 1.44 1.77 0.00000047 
 2‡ 3 54.8 87 1.59 1.74 0.00048 
 3† 2 42.4 67 1.58 1.69 0.0069 
 4 1 29.9 39 1.31 1.34 0.86 
2-23 months 1† 9 57.3 80 1.40 2.14 0.0014 
 2† 1 8.6 20 2.32 2.57 0.020 
 3† 2 12.2 25 2.04 2.31 0.024 
 4 2 12 19 1.58 1.69 0.614 
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 5 1 7.9 11 1.39 1.43 0.999 
24-59 months 1‡ 6 90.6 128 1.41 1.71 0.00025 














 All ages 1‡ 9 100.9 132 1.31 1.76 0.00092 
Under 14 
years 
1† 9 88.2 115 1.30 1.75 0.0035 













All ages 1† 8 37.8 54 1.43 1.98 0.037 
 2 1 5.2 8 1.55 1.6 0.995 
Under 14 
years 
1† 9 38 52 1.36 1.99 0.046 
 2 1 4.4 7 1.58 1.64 0.995 
















All ages 1 1 5.2 10 1.92 2.02 0.63 
 2 2 11.2 17 1.52 1.63 0.76 
Under 14 
years 
1 1 4.8 10 2.07 2.20 0.49 
 2 2 10.4 15 1.45 1.53 0.941 
Under 5 years 1 4 19.8 29 1.47 1.69 0.36 














All ages 1 1 1.3 4 2.96 3.42 0.61 
 2 1 1 3 2.93 3.25 0.87 
Under 14 
years 
1 1 0.8 3 3.62 4.18 0.56 
 2 1 1.1 3 2.74 3.11 0.88 
Under 5 years 1 1 1 3 2.91 3.35 0.79 
 2 6 5.1 8 1.58 2.16 0.86 
 
 
4.2.2 Cluster analysis 
Maps of the statistical clusters are presented in Figures 14 through to 19. Most likely 
clusters (the first identified and most significant cluster), are highlighted in colour to show 
the regions contributing to the cluster. Colours are representative of the age group that 
make up the data, with the all ages group coloured green, the Under 14 years group 
coloured red, the Under 5 years group coloured blue, the 24-59 month group coloured 
yellow and the 2-23 month group coloured purple. When appropriate, secondary clusters 
and even tertiary clusters are presented using barred lines to indicate the hierarchy. Clusters 
were only deemed relevant to this study if they had no geographical overlap with the next 
significant cluster, as this would result in the same data being used twice, inferring a higher 
rate of disease than reality. Clusters with significant secondary and tertiary results were still 
mapped and presented below, however a second version of the map was also produced to 
use for analysis. All data for all figures below can be found in Table 17.  
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Figure 14 shows the most likely cluster of IPD cases across all ages and all times 
(green). The cluster is central, including the main city and its outskirts. Adjusting for Under 
14 (red) and Under 5 (blue) has no effect on the cluster, which remains in the same place for 
both analyses. The RR increases as the age group narrows, starting at 1.48 to 1.50 to 1.58. 
The final map in the figure (yellow), shows the most likely cluster in the 24-59 month group 
which has shifted up and away from the initial central cluster towards the northeast. The RR 
has also increased to 2.10. Interestingly, this cluster does not include Basse or surrounding 
townships.  
 Figure 15 shows the three significant clusters from different age groups during the 
first 24 month period. All include the central regions, but the All Age group has one fewer 
region involved, while both Under 14 and Under 5 include two regions on the southwestern 
edge of the cluster. The RR again increases as the age categories narrow, starting from 1.86 
(green), up to 1.92 (red) and finishing with 2.07 (blue). Of note is the inclusion of the furthest 
southwestern region, which is the city of Gambisara, which reported the highest number of 
IPD cases per settlement (25) across all time periods (data not shown).  
Figure 16 shows the clusters associated with RCP and describes the entire time 
period. This is also the first example of multiple clusters. The All Age group shows a central 
cluster just to the east of Basse (RR: 1.53), while the secondary cluster includes the furthest 
east regions, and has a RR of 1.28, while the third and final significant cluster (RR: 1.30) is 
just to the west of Basse township, and includes the outskirts along the riverbank (to the 
north of the study region). The Under 14 group and Under 5 groups have the same 
geographical locations for both primary and secondary clusters, and following suite with all 
previous clusters, RR increases as age groups narrow (RR primary: 1.51 to 1.53, RR 
secondary: 1.36 to 1.37). The final map on this page shows a single region clustering cases of 
RCP in the youngest age group, 2-23 months (RR: 1.99). On the next page, the remaining two 
maps are presented, with the last age group (24-59 months) in yellow. RR of the most likely 
cluster is 1.40. Although not included in the analysis, it is interesting to note that the 
secondary and tertiary clusters in this group serve almost as a bridge to connect the central 
and easternmost regions, which are divided in other age groups.  
Figure 17 spans three pages and presents RCP clusters in all age groups during the 
first 24 months of the study period. Not unlike the first 24 months of IPD cases, all clusters 
are central in location, and include the capital city. The RR does not increase linearly with 
decreasing age groups as previous clusters have, although it does end with its highest value 
in the youngest group at 2.14.  
Figure 18 shows the clusters resulting from an analysis of VT cases across the age 
groups throughout the entire study period. All three clusters are identical, although the RR 
varies from 1.76 to 1.75 to 1.93 with decreasing age groups. These three clusters, and their 
stationary movement through age groups are the same as the overall IPD cases in Figure 14, 
with the only difference being the increased RR for VT cases in the cluster.  
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Figure 19 describes the same analysis as above, only using the first 24 months instead 
of the entire time. Clusters remain central and they include the largest RR to date, 2.23 in 
the Under 5 group (blue).  








Figure 14. Cluster analysis of IPD cases by age group across the entire study period.  
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Figure 17 (right). Cluster analysis of RCP cases by  
age group across the first 24 months  
















Figure 19. Cluster analysis of VT cases by age group across the first 24 months of the study period.
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4.2.3. Risk surfaces 
 Using adaptive kernel smoothing, the following maps show three dimensional risk 
surfaces, which plot one disease against the other. This allows comparisons between 
diseases, showing areas with high or low rates in relation to each other. Longitude and 
latitude are described on the x and y axes respectively, while the colour scale on the right 
hand side denotes z-values, or the rise and fall of the 3 dimension of each surface. A red to 
yellow colour gradient is used to represent the height of the graph on the z-axis. Red 
indicates higher rates of IPD (or NVT), while yellow/white indicate higher rates of RCP (or 
VT). Significance levels are drawn using solid or dotted lines for high and low values 
respectively.  
Figure 20 to 24 show risk surfaces for each age group across the entire study period. All 
surfaces show a similar trend, with a significantly higher portion of IPD cases in the western 
region, with a significantly lower portion of RCP in the eastern region. Closer inspection 
reveals differences, such as a significant peak of IPD in the north part of the central region, 
which has a wide area of significance when all ages are taken into account, but which drops 
down to a much smaller area for Under 14s, and disappears entirely in the Under 5 group. 
This returns to a large area of significance in 24-59 months, but drops down again to very 
small peaks between 2-23 months.  
 
 
Figure 20. Adaptive kernel smoothing risk surface of IPD (B - red) and RCP (A - yellow) across 




Figure 21. Adaptive kernel smoothing risk surface of IPD (B - red) and RCP (A - yellow) across 
cases under age 14 and taken throughout the entire time period.  
 
 
Figure 22. Adaptive kernel smoothing risk surface of IPD (B - red) and RCP (A - yellow) across 





Figure 23. Adaptive kernel smoothing risk surface of IPD (B - red) and RCP (A - yellow) across 
cases from 2 to 23 months and taken throughout the entire time period.  
 
 
Figure 24. Adaptive kernel smoothing risk surface of IPD (B - red) and RCP (A - yellow) across 





 Figures 25 to 27 show the risk surfaces of VT (yellow) compared to NVT (red) across 
the whole time period. A significant peak in the All ages group in the west gets smaller with 
each successive age group reduction. The central remains clearly yellow throughout each 
age group, with a small trough of significance occurring in the Under 14 group and Under 5. 
The eastern region is mostly equal, showing orange, indicating even rates of VT and NVT in 
the area.  
 
 
Figure 25. Adaptive kernel smoothing risk surface of VT (C - yellow) and NVT (D - red) across 
cases of all ages and taken throughout the entire time period.  
 
 
Figure 26. Adaptive kernel smoothing risk surface of VT (C - yellow) and NVT (D - red) across 






Figure 27. Adaptive kernel smoothing risk surface of VT (C - yellow) and NVT (D - red) across 
cases under age 5 and taken throughout the entire time period.  
 
4.3 Before and after vaccine comparison 
4.3.1 SaTScan hotspot analysis 
 Using the same technique as before, datasets were scanned for clusters of higher 
observed rates than should be expected as well as spatial proximity of cases. Age groups 
were reduced from five to two, in order to conserve data lost during the between “Before” 
and “After” periods resulting in an Under 5 group as well as a “5 and above”. Table 18 below 
describes the results from the SaTScan program. Only half of the groups had significant 
clusters, including only a single IPD group (Under 5 during the Before period). The Under 5 
group in the Before group for RCP also showed significance for three clusters, including two 
that qualified as extremely significant. RR varied much more than Table 17, with values as 









Table 18. Spatial statistics of cluster analysis during before and after time periods 












O/E RR p values 
Before 
(IPD) 
Under 5 1† 9 40.5 56 1.38 2.07 0.026 
5 and 
up 
1 1 1.52 5 3.28 3.74 0.345 
 2 5 7.8 12 1.54 1.91 0.834 
 3 1 1.24 3 2.41 2.57 0.952 
After 
(IPD) 
Under 5 1 2 5.2 10 1.92 2.12 0.59 
5 and 
up 
1 1 0.56 3 5.36 6.67 0.269 




Under 5 1‡ 6 128.6 183 1.42 1.74 0.000002 
 2‡ 3 55.3 87 1.57 1.72 0.00094 
 3† 2 42.8 68 1.59 1.70 0.0065 
 4 1 30.2 39 1.29 1.32 0.878 
 5 4 96.3 106 1.10 1.13 0.998 
5 and 
up 
1 1 7.87 17 2.16 2.30 0.094 
 2 3 23.5 34 1.45 1.57 0.384 
 3 2 13.9 18 1.29 1.33 0.993 
After 
(RCP) 
Under 5 1‡ 10 235.5 283 1.20 1.48 0.00093 
 2† 3 64.4 98 1.52 1.65 0.0012 
 3† 2 47.4 71 1.5 1.58 0.037 
 4 1 32.9 42 1.28 1.30 0.896 
 5 2 41.4 50 1.21 1.23 0.974 
 6 2 27.8 33 1.19 1.20 0.999 
5 and 
up 
1† 1 4.52 14 3.10 3.46 0.014 
 2 2 9.2 15 1.63 1.75 0.726 










4.3.2 Cluster analysis 
 Maps of statistical clusters are presented from Figure 28 to 31. As in the previous 
section, most likely clusters are highlighted on the map, in a colour representing the age 
group (Under 5 is turquoise, and 5 and over is orange). Only one significant IPD cluster was 
found in the Before group, and none in the After, while two RCP clusters were identified in 
the After group, one in each age category, with a single cluster located in the Before group 
as well. Figure 28 shows the lone IPD cluster, occupying the central regions beforehand, with 
a RR of 2.07. Figure 29 shows a reasonably similar central cluster, reaching further north 
rather than south, but otherwise sharing many characteristics as Figure 26, although with a 
lower RR of 1.74. Figure 30 however shows a large cluster taking up all of the easternmost 
regions, reaching almost all the way in to the centre. This is the largest cluster observed 
across all forms of analyses, although it has one of the lowest RR (1.48). Finally, in Figure 31, 
the sole group over the age of 5 is shown, which consists of just a single region. It also 
happens to hold the highest significant RR, with a value of 3.46 – almost double all of the 




Figure 28. Cluster analysis of IPD cases under the age of five and during the first two years of 





Figure 29. Cluster analysis of RCP cases under the age of five and during the first two years 
of the study (RR: 1.74, p < 0.001). 
 
Figure 30. Cluster analysis of RCP cases under the age of five and during the last two years of 





Figure 31. Cluster analysis of RCP cases aged five years and older, taken during the last two 
years of the study (RR: 3.46, p = 0.014).  
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Chapter 5 – Discussion 
 
This chapter discusses the results presented in the previous chapter, and provides 
speculative answers to explain them. Section 1 deals with the difficulties arising from 
existing literature, while Section 2 describes the case characteristics. Section 3 examines the 
case characteristics of those with both diseases, followed by Section 4 with the vaccine 
serotype analysis.  Section 5 covers incidence rates, while Section 6 and 7 discuss the cluster 
analysis and risk surface analysis respectively. Section 8 describes the results from the 
second research question, the before and after comparison. Finally, Section 9 finishes the 
chapter off with a review of the strengths and weaknesses of the thesis, including an 
examination of potential confounders and sources of bias.  
 
5.1 Overview 
As discussed in Chapter 2, there is a lack of directly comparable studies which 
examine the burden of IPD and/or RCP at a regional level using spatial statistics or clustering 
analyses, particularly as part of a response to a vaccine program. As a result, many of the 
results here are unique in their existence, and difficult to interpret other than through 
general comments and speculation. One such example is the adaptive kernel smoothing risk 
surfaces produced in Section 4, which are of a novel design and do not appear in any other 
pneumonia related study to date.   
Despite this, there is no shortage of studies examining pneumococcal disease before 
and after vaccination, which can help explain some of our findings, as well as a number of 
studies describing the effects of clustering using other infectious respiratory conditions.  
 
5.2 Case characteristics 
With the introduction of PCV-7 and then PCV-13 in the Gambia, concerns over the 
vaccine’s impact were raised, sparking the creation of a surveillance project to monitor the 
effect on the population. This thesis examines IPD and RCP, and to a lesser extent, compares 
VT and NVT, with regards to their geospatial distribution. Demographic comparisons 
between the IPD and RCP showed a few significant proportional differences in ethnicity, first 
dose of PCV, and age groups, although for the rest of the groups, were very similar. The 
differences in ethnicity are most likely not a result of any biological difference, but simply 
due to clustering of common ethnicities together, which would make the spread of a single 
organism much more likely to affect another person of the same ethnicity. The differences in 
the age groups suggest that IPD occurs sooner earlier in children, as almost 50% of cases 
occurred within the first two years, while only a fifth of RCP cases did. Conversely, RCP 
seems to be more likely to develop after the first two years. Previous comparisons of IPD 
and RCP have shown similar results, albeit with smaller age groupings [104].  
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5.3 Comparison of IPD to RCP to Both 
Cases that had both IPD and RCP were significantly different in almost every way, 
showing much higher average ages and median ages, in addition to being predominantly 
male (80%). This can be seen in the age group breakdown, which shows that 48% of the 
cases were above the age of 14. While the vast majority of adults remain relatively free from 
pneumonia and IPD relative to children, these high findings suggest that disease obtained at 
an old age is a) more severe, or b) leaves the body more susceptible to other diseases. This 
middle group with both diseases also showed low rates of vaccination, with only a quarter 
having received their PCV vaccination. 
 
5.4 Serotype analysis 
Serotype analysis showed VT cases were much older than NVT cases, with an average 
of 87 months to 51, and a median age of 32 months to 10. Interestingly, only 28% of the VT 
group had received the first PCV dose, and only 22% of them had received all three doses. 
This low rate, especially when compared to NVT groups (with 64% and 45% respectively), 
suggests that VT disease is affecting people who have not received the vaccine, and could be 
prevented by higher coverage of PCV-13. Conversely, in the NVT group, the higher 
vaccination coverage seems to have protected against VT disease, resulting in 
nasopharyngeal replacement with NVT serotypes, which are affecting children at a younger 
age.  
Frequency of serotypes were analysed as well, showing varying counts of the 13 VT 
serotypes, with serotypes 1 and 5 accounting for over 60% of the cases alone. With the 
addition of 6A/B and 14, these four account for 80% of the cases. In the NVT cases, the 
majority were caused by individual serotypes, with frequencies ranging from 1% to 6% of all 
cases, with the exception of serotype 12F, which was responsible for 31% of NVT cases, 
implying a heavy burden of disease attributable to this specific serotype. In a surveillance 
study of a 10-valent vaccine trial in Brazil, dos Santos et al. [105] showed high rates of 5, 1, 
6B and 14 in children aged 2 to 15, while 7F appeared to affect older age groups (>15 years). 
These same serotypes appear in our study, in addition to 6A which was included in the PCV-
13, while 7F did not occur.  
 
5.5 Incidence rates 
Incidence rates were presented showing varying trends across time. Overall IPD cases 
Under 14 years showed a peak in 2010 with 82 cases/100,000 dropping to the lowest in 2013 
(29/100,00), before rising slightly to 44/100,000 in 2014. In comparison, the overall Under 
14 RCP had one of its lowest rates in 2010 (263/100,000) with a peak in 2012, which was as 
high as 521/100,000. Overall IPD cases in the Under 5 group showed a similar trend, with a 
rising rate peaking in 2010 (164/100,000), falling all the way to 2013 (60/100,000), and then 
with a slight increase in the final year (92/100,000). Overall RCP rates in the Under 5 
category were very similar to the Under 14 group, with a peak in 2012 (1187/100,000), with 
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2010 being the second lowest rate after the first year of collection. The first year of data 
collection, 2008, as mentioned in the results section, was not a full year of data collection, 
and these numbers are likely an underestimate of the true values. Both diseases have higher 
rates in the Under 5 group than the Under 14 group, meaning that IPD and RCP affect 
younger children more than older children. Further research and a more in-depth 
breakdown of VT and NVT serotype incidence rates can be found [106]. One of the major 
current projects to compare IPD and RCP, the LEAP study, based out of Latin America [107], 
shows comparable rates and characteristics of cases in relation to each other. Despite using 
slightly different age groups (1-36 months), incidence rates were found to be 76.4/100,000, 
while RCP showed 9983/100,000. Our Gambian study had lower, yet comparable rates of 
IPD, as well as a tenfold difference in RCP, some of which may simply be a result of differing 
sample sizes and age groupings [32]. Additionally, Andrade et al. [108] performed a similar 
analysis in Brazil, where they found RCP rates of 1751/100,000 and IPD rates of 
54.9/100,000, showing much more similar results to this Gambian study.   
 
5.6 Cluster analysis 
In the output table of the SaTScan cluster analysis, IPD cases were found to be 
clustered in the 4 oldest age categories, but with no evidence of clustering in the youngest 
group. From what we saw earlier regarding the higher rate of IPD in the youngest age group, 
this suggests that although there may be more cases proportionally in that group, they are 
less spatially related. In the 1st 24 month time period, one cluster was detected for each of 
the main three age groups, although none could be found in the subcategory groups, which 
is most likely due to small sample sizes, rather than any true lack of clusters.  
In most instances, RCP showed several clusters per age group in both Overall time 
and 1st 24 month time period. Secondary clusters are not calculated using the same data 
from the first cluster, and so represent an additional source of clustering, even if they occur 
over the same area. VT clusters are present in all age groups and time periods analysed, and 
vary very little between themselves. NVT has no significant clusters for any age grouping or 
time period.  
When analysing the clusters themselves, starting with IPD in the baseline group, or 
the 1st 24 month time period (Figure 15), we see three similar clusters for the three age 
groups, with All ages stretching further to the northeast than Under 14 or Under 5, but all 
three remaining relatively central and tight. Compared to RCP at the same time period, All 
ages has exactly the same clustered regions as IPD, while Under 14 have similar central 
“core” regions to RCP, but differs in the direction and location of the additional regions. IPD 
has significant clusters slightly west of the city, while RCP’s additional clusters are to the 
northeast. Under 5 clusters are similar to Under 14 both in regards to IPD and RCP clustering 
location.  
Observing the whole time period, many of the clusters have branched out, and occur 
not only in the central few that featured in virtually every 1st 24 month cluster, but also 
along the extremities of the study area. IPD remains relatively centralised, for All ages, 
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Under 14 and Under 5, map identically, while the fourth (24-59 months) shows a cluster that 
is up to the northeast of the others and does not include the central core regions. RCP on 
the other hand, has expanded, so that while the most likely cluster is still just to the east of 
the central region (Figure 16), there are also secondary clusters along the edge of the map 
for all other age groups. In the case of 2-23 months, the primary cluster is actually located 
here. Perhaps most interesting of all, is the 24-59 month group, which has a primary cluster 
that spreads across from the centre to the east, with secondary clusters that reaffirm the 
clusters seen in All ages, Under 14 and Under 5. Two studies by Mouro et al. and Tanskanen 
et al. showed evidence of clusters of IPD in their papers, but other than acknowledging that 
there were clusters, they focused more on the risk factors within the clusters [109, 110].  
All three age group comparisons of VT are very similar, with a tight cluster around the 
central regions in the 1st 24 month group, expanding to surrounding regions in the overall 
group.  
5.6.1 Cluster analysis conclusions 
Upon comparing cluster analyses, it becomes immediately obvious that there is a 
difference in how IPD and RCP map, with IPD tending to be a smaller significant cluster 
around the core central regions, while RCP has different clusters, not only in the centre, but 
also further to the east. Using the first 24 month time period reveals similar, if muted 
effects, with IPD clusters remaining even smaller, while RCP clusters overlap on themselves. 
All age groups report similar effects, with some slight variation of one or two regions across 
the three main age groups. IPD age groups 2-23 and 24-59 months did not have significant 
clusters consistently across all time periods. This by itself indicates a difference between the 
two, as RCP had significant clusters across all age groups, and all time periods. IPD cases 
therefore appear to be more spread out across the regions in their subgroups, while RCP 
cases tended to occur in the same regions with other cases. This could indicate that RCP 
cases have a wider spread from a single case, which would result in a small cluster forming 
around the first case, whereas IPD did not spread as quickly in the area, which might lead to 
fewer secondary cases, and therefore smaller cluster numbers, with some groups having no 
significant clusters [105]. 
 
5.7 Risk surfaces comparison 
The risk surfaces allow a direct comparison of IPD and RCP, or VT and NVT. The first 
surface (Figure 20), describes the overall time period, with all age groups included, and 
shows a West to East downward slope, with high ‘peaks’ of IPD in the western regions, and 
low ‘troughs’ in the east. There is a significant peak that appears to the northeast of Basse, 
which does not feature prominently in other age group surfaces. This area is also the 
location of the cluster in Figure 14 in the 24-59 age group. As the age groups get younger, 
the significant regions shift inwards to the central regions, until in the Under 5 group, they 
are at the furthest central they get. From the cluster analysis, we know that RCP has clusters 
in the east, whereas IPD is still quite central in its clustering. The large portion of 
white/yellow on the right hand side indicate that not only is there significant clustering of 
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RCP in the east, but it far outweighs any IPD cases in that region. Interestingly, the cases 
balance themselves out when compared during the lowest 2-23 age group surface, with only 
minor significance along the furthest edges. By contrast, the 24-59 month group has two 
significant peaks, one in the far west, and another to the northeast of Basse, while RCP has 
one significant trough at the far east.  
When comparing VT and NVT, all three age group comparisons show a significant 
peak of NVT in the same western region as the IPD was found in the previous paragraph. The 
majority of the rest of the surfaces are predominantly yellow, or VT, which shows that there 
is only one region where NVT are occurring at any noticeable rate.  
5.7.1. Risk surface conclusions 
Inspection of the risk surfaces points towards high IPD rates on the western end of 
the province, as well as one to the north east of Basse exclusively for children aged 24-59 
months. RCP continues to show significance in the eastern end, perhaps as a result of the 
decreasing mobility and distance barriers. The main road from the coast bisects the region 
from the western end of the study area all the way to Basse in the centre at which point it 
turns south and out of the country into Senegal. In order to reach any settlements past 
Basse, secondary roads are required, some of which have variable road conditions, and some 
which end up being no more than single-user dirt walking paths. While the landscape 
remains homogeneous across the BHDSS area, accessibility is much greater in the western 
end, with the paved road promoting through traffic, in addition to lying roughly midway 
between the two major health centres in the region, Basse Health Centre, and Bansajang 
Hospital (lying just outside the study region in the Central River Region). While no cases 
were referred from the Bansajang hospital, as it is not part of the BHDSS, the MRC has strong 
ties here, and it is part of several other projects, suggesting that there may be some 
movement between the two, or at the very least, more community engagement.  
 
Conclusion 
The aim of this first research question was to identify if IPD and RCP mapped 
differently, and if so, how they differed. The cases themselves differ in characteristics, both 
regarding age groups, and vaccination status. Cases that have both diseases vary significantly 
to either disease, with regards to sex, age, and age groups. Having both IPD and RCP appears 
to be much more common in men in their twenties, which in turn affects the age group 
ratios, since the majority of the other cases from both other groups are children. As the 
subset of IPD, VT and NVT different significantly in age, age groups and vaccination status, 
the possible results of which have been speculated on above.  
Education has been shown to have a strong effect on pneumonia and IPD, and early 
recognition and treatment could prevent the length of time a contagious patient is around 
others [111], or take steps to lessen the severity. Additionally, these cases only represent the 
cases that presented to an outpatient clinic, not the true burden of disease. If IPD was more 
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easily recognised and acted upon in this area of increased mobility, it would stand to reason 
that there would be more cases reported in the west.  
VT serotypes were predominant all across the map and ages, with a small central 
area of significance, just to the east of the central core regions. NVT clustered significantly 
on the westernmost side, where we previously saw high rates of IPD, suggesting that the IPD 
occurring in this area are a result of pneumococcal replacement. If we assume that the 
previous paragraph’s conclusions are true, and that mobility and engagement are factors 
affecting the distribution of IPD cases, we can further postulate that this area has had a high 
rate of vaccination success, which in turn would result in more participation in health 
services, and a higher willingness to report IPD cases when they occur.  
RCP’s distribution in the east may be a result of the isolated villages, and increased 
transmission within the close-knit communities. If the cost of bringing a child to a hospital 
when the disease is only suspected is too high, then we would expect to see increasing 
numbers of cases in this area due to longer transmission opportunities. There are also 
significant clusters in this region of RCP cases, which indicate a greater number of cases 
occurring here, lending strength to the theory that a longer transmission period results in 
more cases, and that accessibility and mobility barriers could result in a longer time of 
contagious transmission.  
 
5.8 Spatial difference before and after vaccination 
Comparing Before and After time periods using spatial scan statistics resulted in 1 
significant cluster of IPD cases (Under 5 year olds in the Before category), and 3 significant 
clusters of RCP cases (1 Before and Under 5, with the final two After, for both ages). Looking 
at IPD, the occurrence of a cluster indicates too many cases than should be occurring in too 
small a space. After introduction of PCV however, this cluster has disappeared, or at least, is 
no longer statistically relevant, demonstrating not only a decrease in raw case numbers (see 
incidence calculations), but also a decrease in spatial cohesiveness. With regards to 
infectious diseases, a decrease in clustering represents a success for the disease 
management system, since it reduces the number of outbreaks stemming from a single case 
[112].  
RCP cases below 5 provide the only significant before and after clustering set, and 
the result is quite striking. During the before period, a central cluster of RCP cases are 
located in the central six core regions, while the after period shows that the cluster has 
shifted to the east, and has grown to encompass all ten regions in the eastern half of the 
map. While a change of this magnitude likely has several underlying factors, the fact that it 
coincides with the introduction of a pneumococcal conjugate vaccine must be considered.  
Although the final year showed a slight decrease in incidence rates after a peak in 
2011, overall RCP rates grew as the time period went on. This is perhaps a result of NVT 
serotypes causing non-invasive disease, or even VT serotypes that are protected against 
resulting in a less severe, non-invasive reaction. Other bacterial agents might have increased 
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their carriage, with protection against the pneumococci freeing up space in the nasopharynx 
[113], and other viral agents may have simply taken the opportunity presented [114], but 
regardless of the exact reason, some aspect of PCV-13 caused a significant shift in RCP cases 
before and after introduction of the vaccine.  
The final cluster offers a glance into the distribution of RCP in the older age group. 
While these cases were spread out before the introduction of the vaccine, afterwards they 
remain in a tightly packed region. Possible explanations for an increase in RCP clustering is 
provided above, all of which may be relevant here as well.  
 
5.9 Study characteristics 
Strengths 
Due to the number and quality of people working in the BHDSS and PSP projects, this 
study was fortunate to have several advantages that set it apart from others. Firstly, the 
entire surveillance system has been set up exclusively for pneumococcal research, allowing 
for a specialised team of experts in the field to work cohesively. Standardised criteria 
allowed for replicability everywhere, as well as ensuring quality control at the same time. 
Multiple checks occur throughout the data collection period. One of the most subjective 
measurements in the study was the reading of chest x-rays, which was undertaken by two 
qualified readers based on WHO criteria [33], and confirmed with a third. Background 
demographic information was plentiful, and although not presented here, additional 
characteristics may be used for future studies. Up to date population information also 
allowed for very precise rates to be calculated, and due to the length of the study, allowed 
for trends to emerge. The use of chest radiographs provides a high specificity for pneumonia 
and is considered one of the gold standards around the world [85]. 
In addition, the adaptive symmetric kernel smoothing approximation technique is 
arguably one of the most advanced in the world at the time of writing, and allows for a much 
more detailed and statistically appropriate analysis.  
 
Weaknesses 
Despite the best efforts of the surveillance team, as with any large organisation with 
as many moving parts as the BHDSS, there will inevitably be some discrepancies: filling out 
the CRFs, entering data, and all other administrative tasks. With roughly 160,000 DSS 
members to keep track of, some people are missed, and no surveillance round is completed 
without some missing data, simply by nature of the size and complexity. While these are 
unfortunate realities, we can account for them in realising that all data resides with a small 
source of error, something many data sets contain intrinsically. Reporting bias may exist with 
the cases that present at health facilities only representing those people who have chosen to 
come to the hospital. A study by [115] identified some of the factors that influenced whether 
or not rural Gambian women brought their sick child to a hospital, including a broad scope of 
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social, cultural, and economic reasons. We have no reason to believe that cases of IPD or 
RCP are affected by these choices one way or the other, and so despite these biases, they 
should not affect the results disproportionately in any direction.   
Statistical analysis of clusters were aggregated to regional levels in order to use 
known populations. While this provides good generalisability and ease of interpretation, it is 
subject to the modifiable areal unit problem (MAUP), which may dilute a significant event if 
it is surrounded by sparse events [116]. Cluster analysis was also measured by year, which 
does not account for seasonality, a potentially confounding factor [117]. Other confounders 
which may have had an effect include malaria rates, HIV rates, parental education, 
malnutrition, SES, and crowding [118, 119, 120, 121]. All of these factors except HIV status 
were measured but not included in analysis, due to the size and complexity of geospatial 





Chapter 6 – Conclusions 
 
This chapter sums up the conclusions made in the previous chapter, as well as the 
entire project, while Section 2 identifies areas of work needed going into the future.  
 
6.1 Summary 
The impact of pneumococcal conjugate vaccines is having a noticeable effect on IPD 
and RCP cases across time and age groups. The differing characteristics of the diseases 
showed initial geographic similarities at baseline, which have diverged as the time period 
goes on. Clusters are expanding and shifting locations for both diseases, while hotspots of 
disease continue to pop up throughout different time periods. Trends from the incidence 
rates show movement across the time period, giving a better indication of response to the 
vaccine in terms of raw numbers, if not spatial distribution. The overall reduction in IPD 
cases indicates intermediate success for the PCV-13 program, while the hotspots of both VT 
and NVT serotypes indicate areas to focus on moving forward. Risk surface maps highlight 
the proportional differences between IPD and RCP with regards to the geographic regions, 
revealing a west-east gradient that had not been identified prior to kernel smoothing.  
 
6.2 Future work 
 Although this project has shown significant proof of the previously unknown 
geographic burden of IPD and RCP in rural Gambia, there is still much work to be done in this 
field. As previously discussed in Chapter 2, there are many risk factors that influence rates of 
both IPD and RCP, many of which are already collected as part of routine surveillance. An 
analysis of these variables, coupled with current geographic analyses may reveal further 
results in the relationship between IPD and RCP.  
The cluster analysis of this thesis was conducted using specific BHDSS regions, 
created for the purpose of easily monitoring the population. While still able to show 
meaningful and significant results, it would also be interesting to see these same clusters 
analysed using settlement level data. Although the dataset required for this analysis 
increases dramatically from approximately 28,000 data points in the current analysis, to 
roughly 320,000, it would offer a much more accurate picture of disease clusters in the study 
area.  
The information provided by clustering regions of VT and NVT could indicate areas 
for future study within the PSP itself, as they show clear areas where the vaccine is having an 
effect, as well as areas that do not appear to have been as successful. Increasing coverage 
and monitoring these regions could produce some interesting results for the next study 
With regards to pneumonia mapping in general, this area is woefully 
underrepresented in both the literature and current projects. With advances in simplicity 
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and relatively low cost of using GIS programs to map and analyse disease, pneumonia 
research has a long way to go in order to fully make use of the tools available. Some studies 
have used GIS programs to effective results in developed countries, but with the burden of 
childhood pneumonia affecting areas like Sub-Saharan Africa and South-East Asia so 
severely, there are many places that would benefit considerably from the multifaceted 
approach afforded by GIS programs. While these locations are often hindered by poor, or 
non-existent spatial data, it would only take a moderate amount of work to map, which in 
turn would allow for the spatial data to be used across all platforms, not just health related, 
making it a worthwhile endeavour by anyone’s consideration.  
Although this study and the overarching project do show some exciting new 
developments in management and treatment of pneumococcal disease and pneumonia, 
there remains plenty of work to be done. Pneumonia’s effect on the global population 
continues to be catastrophic, with millions of lives lost every year. Pneumococcal conjugate 
and polysaccharide vaccines do offer safe and effective interventions, however, these 
methods are by no means exhaustive. While a broad spectrum respiratory disease like 
pneumonia may be impossible to eradicate completely, there are many ways its burden can 
be reduced, and under proper management, even controlled. Gambia and other countries 
struggling under similar burdens of disease from pneumonia and pneumococcal disease may 
still be several years away from this goal, but with each project like this one, the goal 
becomes a little bit closer.  
 
6.3 Policy recommendations 
 For policy makers in the world, this thesis has several suggestions to both improve 
research goals and health benefits. Firstly, that the MRC, WHO, and other interested 
stakeholders continue to fund in-depth and high-quality geographical maps of rural regions 
in the developing world. This sort of analysis would not be possible without up-to-date and 
accurate maps upon which to plot the case data. While initial time costs to mapping a region 
may seem prohibitively high (as evidenced by the poor coverage in many remote regions), 
maintaining a properly mapped region requires minimal effort, and the benefits and 
generalisability to the system are endless. Secondly, the impact of PCVs on IPD shows a 
measurable decline in IPD after vaccination. Given the severity and impact IPD can have on 
the human population, PCV programs should be implemented in high risk areas. It is 
important to note that the phenomenon of disease replacement may still play an important 
role in the PCV debate, and should not be forgotten while considering vaccine programs. 
Finally, an effort should be made to focus on areas indicated with the VT and NVT risk maps. 
VT areas suggest the need for more comprehensive vaccination upkeep, while the NVT areas 
should be monitored for the effects of replacement, which in turn may have further effects 
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Appendix I. CRFs 
Appendix II. Frequency counts of NVT serotypes.  
Appendix III. Frequency counts of VT serotypes.  






































































Appendix II. Frequency table of NVT serotypes.  
Serotype Frequency 
Non Vaccine Type (n = 98) 
2 2 (2.0%) 
8 2 (2.0%) 
9A 4 (4.1%) 
9L 1 (1.0%) 
9N 1 (1.0%) 
10A 3 (3.1%) 
10F 2 (2.0%) 
11A 1 (1.0%) 
11B 1 (1.0%) 
12A 2 (2.0%) 
12B 3 (3.1%) 
12F 30 (31.0%) 
13 2 (2.0%) 
15A 3 (3.1%) 
15B 1 (1.0%) 
16 1 (1.0%) 
16F 2 (2.0%) 
17F 3 (3.1%) 
18A 1 (1.0%) 
20 1 (1.0%) 
21 1 (1.0%) 
22A 1 (1.0%) 
24F 2 (2.0%) 
25 1 (1.0%) 
25A 1 (1.0%) 
25F 2 (2.0%) 
33 1 (1.0%) 
33F 1 (1.0%) 
34 2 (2.0%) 
35 1 (1.0%) 
35B 4 (4.1%) 
40 2 (2.0%) 
45 1 (1.0%) 
46 6 (6.1%) 
55 1 (1.0%) 







Appendix III. Frequency table of VT serotypes. 
Serotype Frequency 
Vaccine Type (PCV-13) (n = 222) 
1 93 (41.9%) 
3 3 (1.4%) 
4 4 (1.8%) 
5 45 (20.3%) 
6A/B 25 (11.3%) 
9V 1 (0.5%) 
14 22 (10.0%) 
19A 12 (5.4%) 
19F 5 (2.3%) 
























Appendix IV. Boolean search terms used in systematic review.  
 
Pneumococcal OR Invasive Pneumococcal Disease OR Pneumococc** OR Streptococcus 
pneumonia* OR IPD AND spatial analysis OR geospatial OR mapping OR Geographic 
Information System* OR GIS OR clustering OR distribution 
 
Pneumonia OR Streptococcus pneumonia* AND spatial analysis OR geospatial OR GIS OR 
clustering 
 
Pneumonia OR Streptococcus pneumonia* OR pneumococcus AND spatial analysis OR 
geospatial OR GIS OR clustering 
 
IPD OR Invasive Pneumococcal Disease AND spatial analysis OR mapping OR clustering OR 
distribution  
 
Pneumonia AND Invasive Pneumococcal Disease AND mapping OR spatial analysis OR 
distribution 
 
Pneumonia OR Streptococcus pneumonia* AND GIS OR clustering OR spatial analysis 
 
Invasive Pneumococcal Disease AND clustering OR mapping OR distribution OR spatial 
analysis OR geospatial 
 
IPD AND GIS OR clustering OR spatial analysis 
 
